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 Zusammenfassung 
 
 
Zusammenfassung 
 
 
Diese Arbeit beschäftigt sich mit der Biosynthese von myxobakteriellen Naturstoffen, mit 
Schwerpunkt auf der funktionellen und biochemischen Charakterisierung von Enzymen, die unge-
wöhnliche Vorläufer für biosynthetische Stoffwechselwege zur Verfügung stellen. Es konnte gezeigt 
werden, dass (R)--Tyrosin – ein Bestandteil der Chondramide aus Chondromyces crocatus – durch 
die neuartige Tyrosin-Aminomutase (TAM) CmdF gebildet wird. Mittels gezielter Mutagenese wurden 
Möglichkeiten zur Beeinflussung der Stereoselektivität von CmdF aufgezeigt. Die Klonierung und 
Characterisierung weiterer TAM Enzyme offenbarte einen hohen Grad an evolutionärer Diversifizie-
rung innerhalb der erweiterten TAM Familie. Außerdem wird die Strukturaufklärung und die Biosyn-
these neu entdeckter Metabolite aus Stigmatella aurantiaca beschrieben, welche Imidacine genannt 
wurden. Diese Verbindungen besitzen eine fettsäureartige Grundstruktur, zeichnen sich jedoch zusätz-
lich durch eine äußerst seltene Imidazolacrylgruppe und einen Cyclopropanring aus. Die Biosynthese 
der Imidacine ist abhängig von der Bereitstellung einer Urocansäure-Startereinheit durch eine Histidin-
Ammoniumlyase (HAL), und stellt damit das bisher einzige Beispiel für die Beteiligung von HALs am 
bakteriellen Sekundärstoffwechsel dar. 
Es wurde darüber hinaus ein „Metabolomics“-basierter Ansatz zur vertieften Analyse der Sekun-
därmetabolitenprofile von Myxobakterien entwickelt. Hochauflösende massenpektrometrische Mes-
sungen wurden mit einem statistischen Auswertungsverfahren (PCA, „Principal Component Analy-
sis“) kombiniert, um solche Substanzen zu identifizieren, die signifikante Unterschiede innerhalb einer 
Probenserie mit hoher Komplexität darstellen. Die Anwendung dieser Methode enthüllte die erstaun-
lich hohe Diversität des sekundären Metaboloms der Spezies Myxococcus xanthus. 
 
iii 
Abstract 
 
 
Abstract 
 
 
In this work, the biosynthesis of secondary metabolites in myxobacteria was investigated, with 
particular focus on the functional and biochemical characterization of enzymes furnishing biosynthetic 
pathways with unusual building blocks. A novel member of the tyrosine aminomutase (TAM) enzyme 
family, CmdF, was shown to supply (R)--tyrosine for incorporation into the chondramides by Chon-
dromyces crocatus. Site-directed mutagenesis demonstrated the feasibility of modulating the stereose-
lectivity exhibited by CmdF through genetic engineering. The cloning and characterization of 
additional TAMs revealed a high degree of evolutionary diversification within the emerging TAM en-
zyme family. Furthermore, the structural elucidation and biosynthesis of newly discovered metabolites 
from Stigmatella aurantiaca, the imidacins, is reported. These compounds consist of a fatty-acid like 
scaffold, but additionally feature an unique imidazole acryl moiety and a rare cyclopropane ring. Imi-
dacin formation depends on the supply of an unprecedented urocanic acid precursor by a histidine 
ammonia lyase (HAL), revealing for the first time the involvement of HAL in bacterial secondary me-
tabolism. 
In addition, a metabolomics-based approach for the mining of myxobacterial metabolite profiles 
was devised. High-resolution mass spectrometry, combined with statistical interpretation by principal 
component analysis (PCA), was employed to highlight compounds which constitute significant differ-
ences in a set of highly complex samples. This technique uncovered a strikingly high level of intras-
pecific diversity in the secondary metabolome of Myxococcus xanthus. 
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  1. Natural products in drug discovery  
A.  Introduction 
1.  The role of natural products in drug discovery 
Natural products from microbial sources exhibit a wide range of biological activities and are 
characterized by an extraordinary degree of structural diversity. A number of these so-called 
secondary metabolites are already of medical importance for the treatment of numerous diseases, 
or serve as leads for the development of novel drugs.[1] Most antibiotics are in fact secondary 
metabolites isolated from microorganisms or derivatives thereof, and medicines based on natural 
products account for a high percentage of annual pharmaceutical sales.[2,3] Macrolide antibiotics 
such as erythromycin, the vancomycin family of glycopeptides, and the lipopeptide daptomycin 
(Figure A-1, 1-3) represent examples of valuable anti-infectives discovered from bacteria. These 
and various other compound classes are in clinical use today.[4-6] Besides antibacterial therapeu-
tics, microbial secondary metabolites with potent antifungal, immunosuppressive or cytotoxic 
activity are known (Figure A-1, 4-6).[2,7-9] Natural products from microbial sources are also used 
Figure A-1.  Structural diversity of bioactive secondary metabolites from bacteria (activity and producing organism 
are given in parentheses). 1, erythromycin (antibacterial, Saccharopolyspora erythrea); 2, vancomycin (antibacterial, 
Amycolatopsis orientalis); 3, GE81112 (antibacterial, Streptomyces sp.); 4, daptomycin (antibacterial, Streptomyces 
roseosporus); 5, salinisporamide (cytotoxic, Salinispora tropica); 6, curacin (cytotoxic, Lyngba majuscula). 
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in veterinary medicine, and some are employed in agriculture due to their insecticidal, herbicidal 
or plant growth-promoting activities.[2,10] 
The emergence of clinically relevant pathogens resistant to an increasing number of antibiot-
ics, and the appearance of novel infectious diseases, generate a continued need to discover and 
develop new biologically active lead structures. Natural products from bacteria are believed to 
yield an increased success rate when searching for drug candidates, in comparison with screens 
employing synthetic compound libraries. This perspective is substantiated by the notion that mi-
crobial natural products represent the outcome of an evolutionary optimization process involving 
selection for a specific biological activity.[11] Notably, the chemical complexity and structural 
diversity of bacterial secondary metabolites rivals that of natural products from other established 
sources, such as plants and fungi. However, the biosynthetic potential of certain orders of bacte-
ria, for example the Actinomycetales, has already been extensively exploited for the discovery of 
natural products in the course of the last century.[12] The probability of finding a novel chemical 
structure produced by a species from such phylogenetic groups has therefore decreased, and the 
last several years have consequently seen increased efforts to tap alternative bacterial natural 
product resources. 
Encouragingly, it is estimated that only a minor proportion (as low as 1%) of prokaryotic 
phyolgenetic diversity has been unearthed so far.[10] Thus, the identification of novel bacterial 
secondary metabolite producers is expected to lead to the discovery of many novel natural prod-
ucts with interesting biological activities in the future. This assumption seems to apply espe-
cially to bacterial isolates from habitats which have not been thoroughly investigated.[13] Evolu-
tionary adaption to a specific ecological niche might be a driving force for the production of 
secondary metabolites which help to increase fitness of the producing organism. Moreover, 
novel producers could also be identified in bacterial taxa whose growth characteristics were 
formerly seen as an obstacle to laboratory cultivation, and by investigating bacteria with an un-
usual "lifestyle". Prokaryotic groups which have been established rather recently as viable 
sources of secondary metabolites (when compared e.g. to the streptomycetes) include the cyano-
bacteria,[14] certain bacterial endosymbionts,[15,16] the marine actinomycetes,[17] the pseudomo-
nads and the myxobacteria.[18,19] 
2.  Myxobacteria – promising producers of bioactive secondary metabolites 
Myxobacteria are soil-living, Gram-negative bacteria that exhibit some outstanding charac-
teristics.[20] They can glide over solid surfaces as coordinated swarms and feed cooperatively by 
degrading biological macromolecules or even live prey microorganisms, which is accomplished, 
  2. Myxobacteria 
at least in part, by secretion of lytic enzymes. Myxobacteria are also able to undergo multicellu-
lar development when they encounter starvation conditions. This process begins with the or-
dered aggregation of cells and culminates in the formation of fruiting bodies containing resting 
cells, the myxospores, which are resistant to environmental stress such as temperature changes, 
desiccation, and UV-radiation. When favorable nutritional and environmental conditions are re-
stored, the spores germinate and retransform into viable cells. Myxobacterial fruiting bodies 
vary in shape and size, from simple cell clusters to sophisticated tree-like structures that emerge 
from the surface, and their morphology is routinely considered for taxonomic classification of 
myxobacterial isolates.[21] 
Over the last three decades, the myxobacteria have made their way from exotic organisms 
which gained attention mainly due to their uncommon morphological characteristics and com-
plex lifestyle, to an established source of natural products that exhibit diverse structures and bio-
logical activities.[22,23] More than 7500 myxobacterial strains have been isolated by workgroups 
at the German Research Center for Biotechnology (Braunschweig, Germany; recently renamed 
Figure A-2.  Examples of myxobacterial secondary metabolites (activity and producing organism are given in paren-
theses). 7, epothilon B (antitumor, Sorangium cellulosum); 8, argyrin A (antitumor, immunosupressive, Archangium 
gephyra); 9, chlorotonil A (Sorangium cellulosum); 10, stigmatellin A (antifungal, Stigmatella aurantiaca); 11, sora-
phen A (antifungal, Sorangium cellulosum); 12, tubulysin A (cytotoxic, Angiococcus disciformis); 13, chondrochloren 
B (antifungal, Chondromyces crocatus). 
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to Helmholtz Center for Infection Research), and a high percentage of these have been revealed 
as proficient producers of secondary metabolites. To date, more than 100 basic structures and 
more than 500 derivatives thereof have been discovered from myxobacteria.[24] Many of these 
compounds display structural features that were novel at the time of their discovery. Likewise, 
many myxobacterial natural products have been found to exhibit biological activities that are 
otherwise rarely observed from compounds of bacterial origin, and a number of secondary me-
tabolites from myxobacteria exhibit unique modes of action.[22,23] These findings make the dis-
covery of natural products from myxobacteria especially appealing, because chances are in-
creased to find compounds which may have the potential to serve as novel leads for drug 
development. 
A few selected examples of myxobacterial secondary metabolites are shown in Figure A-2. 
Epothilone 7 and tubulysin 12 act on the cytoskeleton of eukaryotic cells with contrary effects: 
epothilone stabilizes microtubules, while tubulysin inhibits the polymerization of tubulin; either 
mechanism leads to an arrest of the cell cycle and finally induces apoptosis.[25,26] Epothilone ex-
hibits activity against diverse tumor cell lines, and an epothilone lactame derivative was recently 
approved as an anti-cancer drug. Argyrin 8 is another myxobacterial compound with potent anti-
tumor activity as this natural product was shown to exert its main effect through inhibition of the 
proteasome.[27] Stigmatellin 10 and soraphen 11 represent antifungal compounds with different 
modes of action.[28,29] Chondrochloren 13 displays antibiotic activity against a variety of micro-
organisms, and the biological activity of chlorotonil 9 is currently being evaluated.[30-32] 
The striking diversity of myxobacterial natural product structures and biological activities 
has triggered considerable efforts to investigate the corresponding biosynthetic pathways.[23] 
Molecular and biochemical studies continue to contribute to an enhanced understanding of the 
complex biosynthetic machinery that underlies secondary metabolite production in myxobacte-
ria. This knowledge provides the basis for attempts to improve production yields or manipulate 
biosynthetic pathways for the production of "unnatural" structural variants of natural prod-
ucts.[33] During the last ten years, a sizeable number of secondary metabolite biosynthesis gene 
clusters from various myxobacterial genera has been identified and characterized. The genetic 
information obtained thereby paves the way to use the enzymatic machineries encoded by sec-
ondary metabolite biosynthesis-related genes for combinatorial biosynthesis and for the genetic 
engineering of artificial biosynthetic pathways which yield novel compounds, sometimes even 
with predictable structures.[34-37] Furthermore, entire biosynthetic pathways may be transferred 
into heterologous hosts that offer biotechnological advantages, or which are more amenable to 
genetic manipulation than the original myxobacterial producers.[38] 
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Investigating natural product biosynthesis on the molecular level also provides insights into 
the mechanisms by which monomeric biosynthetic building blocks are made and sequestered 
from bacterial primary metabolism to enable secondary metabolite biosynthesis. Deciphering 
these "channeling" processes, as well as understanding in detail the modifications that occur on 
biosynthetic intermediates prior to their incorporation into a natural product, constitutes an im-
portant prerequisite for improving secondary metabolite production in the original producer 
strain or in a heterologous host. Moreover, single enzymes from complex pathways are some-
times found to be valuable biochemical tools, due to the intriguing transformations which they 
are able to catalyze. 
With the advent of the "genomic era", the above research objectives have been greatly facili-
tated by the increasing availability of whole-genome data for bacterial secondary metabolite pro-
ducers. The genomes of the myxobacteria Myxococcus xanthus DK622 and Sorangium celluo-
sum So ce56 were recently sequenced, revealing the latter as the largest bacterial genome known 
to date.[39,40] The strikingly high abundance of typical secondary metabolite biosynthesis-related 
gene clusters in the genomes of these strains suggested that their genetic potential for the pro-
duction of secondary metabolites exceeds by far the number of previously reported compound 
classes from each strain. While this finding may be considered as quite encouraging with regard 
to the prospects of discovering novel natural products from myxobacteria, it highlights at the 
same time the need for improved analytical methods for the detection, identification and charac-
terization of myxobacterial secondary metabolites.  
 
3.  Outline of this work 
The primary objective of this thesis is to study aspects of natural product formation in 
myxobacteria, with particular focus on the identification and characterization of enzymes 
belonging to the ammonia-lyase/aminomutase enzyme family and their roles as suppliers of 
building blocks for secondary metabolite biosynthesis. Two compound classes were 
investigated: the chondramides produced by Chondromyces crocatus, and the imidacins, 
previosuly unknown metabolites from Stigmatella aurantiaca (Figure A-3). 
The chondramides 14 are highly cytotoxic depsipeptides that exhibit several unusual 
structural features, including a rare -tyrosine moiety.[41] Bioinformatic analysis of the 
chondramide biosynthetic gene cluster from C. crocatus Cm c5 revealed a hybrid polyketide 
synthase/nonribosomal peptide synthetase (PKS/NRPS) biosynthetic route and also highlighted 
the gene cmdF, encoding a putative tyrosine 2,3-aminomutase (TAM).[42] CmdF exhibits high 
A. Introduction 
Figure A-3. Structure of the myxobacterial secondary metabolite chondramide C 14 and the structure of imidacin A1
15 proposed in this work. 
similarity to the known tyrosine aminomutase SgcC4 from the enediyne biosynthetic pathway in 
Streptomyces globisporus.[43] However, it is shown here that the chondramides incorporate 
exclusively (R)--tyrosine, in contrast to the (S)--tyrosine-derived unit found in the enediynes. 
To explore the underlying biochemistry, CmdF was heterologously expressed in E. coli and 
biochemically characterized, revealing the protein as a novel tyrosine aminomutase with 
stereochemical preference for the production of (R)--tyrosine, consistent with its proposed 
function to provide the -tyrosine building block during chondramide biosynthesis.[44] In order 
to establish a stronger basis for sequence comparison and phylogenetic analysis of tyrosine ami-
nomutases, the hitherto small TAM enzyme family was further extended by the identification 
and biochemical characterization of candidate genes from Myxococcus and Cupriavidus species. 
The obtained data support a high degree of evolutionary diversification within the expanded 
TAM enzyme family, suggesting that family members may have been acquired by convergent 
evolution.[45] Aiming at identifying structural determinants of product specificity and stereose-
lectivity in TAM enzymes, mutational analysis of CmdF was carried out, yielding a mutant en-
zyme which produced an increased enantiomeric excess of (R)--tyrosine. This finding shows 
the potential to fine-tune the catalytic properties of tyrosine aminomutases by genetic engineer-
ing for their application as biocatalysts or in designed biosynthetic pathways.[45]  
The imidacins 15 represent a novel compound class produced in minute amounts by 
Stigmatella aurantiaca Sg a15.[46]  Structural elucidation of the imidacins revealed an unique 
fatty acid-like scaffold, consisting of an imidazole-acryl moiety linked via a linear alkyl chain of 
variable length to a carboxy group. In addition, the alkyl chain incorporates a rare cyclopropane 
moiety. The highly uncommon imidazol-acryl substructure could be shown to derive from 
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urocanic acid, representing a building block not previously reported for any natural product. 
Urocanate is supplied by the histidine ammonia-lyase enzyme HALSa, which was demonstrated 
by targeted gene inactivation to be essential for imidacin biosynthesis. In addition, HALSa was 
recombinantly produced in E. coli and biochemically characterized. The results of further gene 
inactivation experiments, in combination with feeding studies and the identification of additional 
candidate genes through screening of a transposon library, allowed to eventually identify the 
imidacin biosynthetic gene cluster and deduce a model for imidacin biosynthesis.[46] The data 
presented in this study reveal how a variety of enzymatic activities commonly associated with 
unrelated prokaryotic metabolic pathways cooperate in S. aurantiaca Sg a15 to produce the 
intriguing imidacin structure. 
Another part of this thesis deals with the characterization of myxobacterial secondary me-
tabolite profiles using liquid-chromatography-coupled high-resolution electrospray-ionization 
mass spectrometry (HR LC-ESI-MS). Based on the combined evaluation of mass accuracy, iso-
tope pattern and retention time information, a highly sensitive method was devised for the tar-
geted screening of complex natural product-containing extracts, allowing for compound identifi-
cation with increased confidence. Furthermore, a statistical approach to explore high-resolution 
LC-MS datasets for the presence of compounds which give rise to significant differences in a set 
of samples was established. Principal component analysis (PCA) was employed for statistical 
interpretation; additionally, a new compound-finding algorithm was implemented for the pre-
processing of raw LC-MS data. This data conditioning step was revealed as a crucial prerequi-
site for obtaining meaningful results from a PCA model.[47]  
Motivated by the apparent discrepancy between the genetic potential of Myxococcus xanthus 
DK1622 for the production of secondary metabolites and the small number of natural products 
reported to date from this strain, the metabolite profiles of 98 M. xanthus strains isolated from 
locations worldwide were compared.[48] PCA was used to reveal distinct compounds exhibiting a 
non-ubiquitous distribution in the sample set. This screen revealed a strikingly high level of in-
traspecific diversity in the M. xanthus secondary metabolome. A significant number of poten-
tially novel compounds was identified, suggesting that M. xanthus constitutes a viable source of 
as yet undiscovered natural products. Moreover, the obtained data help to correlate gene clusters 
of yet undefined biosynthetic function to secondary metabolites produced by these pathways. 
Due to its largely unbiased nature, the diversity-oriented approach employed in this work is also 
considered as useful for a wide range of metabolomics-based experiments, and shows promise to 
facilitate the efficient mining of the natural product inventory of various myxobacterial species 
in the future.[49] 
A. Introduction 
 
4.  The basic concepts of PKS- and NRPS-directed biosynthesis 
Secondary metabolites from bacteria are usually the end products of complex multi-step bio-
synthetic pathways. Many bacterial natural products originate from biosynthetic machineries 
consisting of polyketide synthases (PKSs) and non-ribosomal peptide synthetases (NPRSs), 
which act as enzymatic "assembly lines" by catalyzing the stepwise condensation of a starter 
unit with small monomeric building blocks. The building blocks and biosynthetic intermediates 
are tethered through thioester linkages to the terminal thiols of 4'-phosphopantetheine (4’-ppant) 
arms. These essential prosthetic groups are installed by phosphopantetheinyl transferase en-
zymes as covalent modifications onto conserved serine residues located in the carrier domains of 
PKS and NRPS proteins.[50] The biosynthetic logic of PKS and NRPS pathways thus follows a 
so-called “multiple carrier thiotemplate-model”.[51] This section provides a brief overview of the 
mechanisms that form the basis of PKS- and NRPS-directed biosynthesis. 
PKS biosynthetic systems are commonly classified with regard to the organization of their 
enzymatic functionalities and the basic structures of the compounds which they typically pro-
duce. PKSs of one particular architecture, termed "type I", occur widely in bacterial secondary 
metabolism and exhibit a multimodular organization where each module performs one cycle of 
chain extension (Figure A-4 A).[51,52] The minimum module comprises three functions: the acyl-
transferase (AT) domain selects an extender unit, usually the activated form of a short-chain di-
carboxylic acid such as malonyl-CoA, and transfers it onto the 4'-ppant arm of an acyl carrier 
protein (ACP) domain within the same module. A ketosynthase domain (KS) subsequently dea-
carboxylates the extender unit and performs a Claisen-like condensation reaction with the grow-
ing polyketide chain bound to the multienzyme. Additional domains are often integrated into a 
module and contribute to the structural diversity of PKS-derived metabolites: a ketoreductase 
(KR) domain reduces the -keto group to an alcohol, a dehydratase domain (DH) then catalyzes 
the elimination of water to form adouble bond, and finally an enoylreductase (ER) domain may 
reduce this double bond, resulting in a methylene moiety (Figure A-4 A). 
Similar to the modular PKSs, NRPSs carry out the repeated condensation of amino acid 
monomers to yield non-ribosomally synthesized peptide products (Figure A-4 B).[51] The indi-
vidual amino acid building blocks are selected and activated as aminoacyl adenylates by an ade-
nylation (A) domain prior to their loading onto the integral peptidyl carrier protein (PCP) do-
main of the same module. Subsequently, amide bond formation with the growing peptide chain, 
tethered to the PCP of the preceeding module, is catalyzed by a condensation (C) domain.[53] 
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Figure A-4. The basic reactions catalyzed by PKS (A) and NRPS (B) biosynthetic systems. (1), loading of mono-
meric building blocks; (2), chain extension by claisen-like condensation; (3), further modification of intermediates on 
the "assembly line" (grey boxes). The domains that direct each step are shown as filled circles, domains symbolized 
by dashed circles are optional. ACP, acyl carrier protein; PCP, peptidyl carrier protein; KS, ketosynthase; AT, acyl 
transferase; KR, ketoreductase; DH, dehydratase; ER, enoylreductase; C, condensation domain; A, adenylation do-
main; MT, methyltransferase domain; E, epimerase domain. 
 
A. Introduction 
The PCP-bound peptidyl chain may be further modified, for example by N-methylation – usu-
ally performed by an optional methyltransferase (MT) domain integrated into the adenylation 
domain - or by inversion of the amino acid C stereocenter, carried out by an additional  epime-
rase (E) domain (Figure A-4 B). Following the incorporation of cysteine, serine or threonine, the 
side chains of these amino acids may be intramolecularly cyclized and dehydrated to form thia-
zoline and oxazoline rings, respectively, by the action of heterocyclization domains.[51] 
In contrast to the ribosomal synthesis of proteins, NRPS-directed biosynthesis is not re-
stricted to the exclusive use of the standard set of 20 proteinogenic amino acids. Indeed, a size-
able number of A-domains have been characterized which activate and incorporate modified or 
highly unusual amino acids, or even non-aminated short-chain acids or aromatic carboxylic ac-
ids.[51] Furthermore, additional tailoring enzymes can modify individual building blocks or the 
nascent peptidyl chains during NRPS biosynthesis, while these are covalently attached to PCP 
domains. Examples include halogenation and the cross-linking of amino acid side chains.[54,55]   
The products of PKS and NRPS biosynthetic pathways are most often released from the as-
sembly line through the action of a thioesterase (TE) domain located downstream of the last 
module in the respective pathway. TE-catalyzed hydrolysis of the enzyme-bound thioester in-
termediate yields the free acid; alternatively, intramolecular nucleophilic attack onto the TE-
bound acyl chain leads to macrocyclization.[55] The PKS- or NRPS-derived core structures may 
undergo further post-assembly line modifications by the action of dedicated enzymes, with the 
most frequently observed transformations being the introduction or removal of double bonds, 
hydroxylations, glycosylations, acylations, O-, N- or C-methylations, along with rather unusual 
modifications such as epoxidation.[51] 
In textbook bacterial PKS and NRPS biosynthetic pathways, each module in the enzymatic 
assembly line is used only once, and the order of modules and arrangement of domains con-
tained in these modules therefore correspond to the chemical structure of the polyketide or non-
ribosomal peptide product – an observation that has been termed the co-linearity rule.[56] Bioin-
formatic analysis of many PKSs and NRPSs, in combination with the results of structural and 
biochemical studies, has enabled the development of guidelines for predicting the specificity of 
domains responsible for the loading of monomeric building blocks.[53,57,58] Thus, it is (to a cer-
tain extent) possible to devise a hypothetical structure for a compound produced by a PKS or 
NRPS pathway through in-silico analysis of the genes encoding the underlying biosynthetic en-
zymes. If the product structure is known, the deduced biosynthetic functions may be correlated 
to structural features and a biosynthetic model can be developed. However, in recent years the 
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molecular basis for the formation of many myxobacterial natural products has been investigated 
in detail, and these studies have frequently revealed unexpected genetic organizations of biosyn-
thetic pathways and surprising biosynthetic features that challenge traditional textbook biosyn-
thetic logic, such as the iterative use or the complete skipping of modules and the incorporation 
of unusual building blocks and starter units.[56,59] 
 
The chondramides – products of a mixed PKS/NRPS pathway with unsual features. 
The biosynthesis of the chondramides (Figure A-5; see also chapter B-3) provides an illus-
trative example for the aforementioned concepts of PKS- and NRPS-directed biosynthesis. The 
chondramides are highly cytotoxic depsipeptides which are biosynthesized via a hybrid 
PKS/NRPS route in the myxobacterium Chondromyces crocatus.[41,42,60] In fact, a significant 
number of myxobacterial secondary metabolites results from such "mixed" PKS and NRPS 
pathways.[59] The first two multienzymes encoded by the genes cmdA and cmdB in the chondra-
Figure A-5.  Schematic representation of biosynthetic functions encoded by the hybrid PKS/NRPS chondramide 
gene cluster, and proposed assembly-line intermediates during biosynthesis of chondramides C (R = H) and D (R = 
Cl) 16. 
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mide biosynthetic gene cluster contain typical PKS modules, which elongate an ACP-bound ace-
tyl starter unit with three methylmalonyl-CoA extender units. The first extension step is fol-
lowed by ketoreduction to yield a hydroxy group, in agreement with the presence of a KR do-
main and an inactive DH domain, while KR-catalyzed reduction and subsequent dehydration by 
a functional DH domain take place after the second chain extension cycle, resulting in the for-
mation of a double bond between two extender units. Following incorporation of the third propi-
onate unit, complete reduction leads to a methylene moiety – as anticipated with regard to the 
full complement of KR, DH and ER domains found in the last PKS module. Biosynthesis pro-
ceeds via the incorporation of alanine by the single-module NRPS CmdC, followed by conden-
sation of tryptophane to the peptidyl chain, catalyzed by the first module of CmdD. The A-
domain in this module contains an integrated MT domain, which likely accounts for N-
methylation at the appropriate position. The presence of an additional epimerase domain sug-
gests that the tryptophane building block in the final chondramide structure adopts the "unnatu-
ral" D-configuration. Furthermore, some chondramide derivatives exhibit a rare 2-
chlorotryptophane substructure, where the chlorine is introduced by the dedicated halogenase 
CmdE, which is also encoded within the chondramide biosynthetic gene cluster.[42] 
Another striking structural feature of the chondramides is the (R)--tyrosine moiety, which is 
incorporated by the second NRPS module of CmdD (Figure A-5). The biosynthetic origin of this 
unusual building block and its mode of incorporation into the chondramide scaffold are the sub-
ject of chapter B-1,[44] revealing the role of the tyrosine 2,3-aminomutase CmdF in the process. 
CmdF exhibits unprecedented stereochemical preference for the production of R--tyrosine, 
which is consistent with its function to provide the -tyrosine building block for chondramide 
biosynthesis (see also the following chapter A-5 and chapter B-2). 
The chondramide biosynthetic pathway from Chondromyces crocatus shows a high level of 
colinearity between genes in the cluster and the predicted biochemical steps required for 
chondramide biosynthesis.[42] In contrast, the biosynthesis of the imidacins by the myxobacte-
rium Stigmatella aurantiaca, which is described in chapter B-4, only follows the rules of text-
book biosynthetic logic to a low extent. The unique urocanate building block for imidacin bio-
synthesis is also supplied by a member of the ammonia-lyase enzyme family. Therefore, the 
following chapter provides an overview of the general characteristics and functions of ammonia-
lyase and aminomutase enzymes. 
  5. Ammonia-lyase and aminomutase enzymes 
5.  Aromatic amino acid ammonia-lyase and aminomutase enzymes as suppliers 
of building blocks for natural product biosynthesis 
 
Enzymes of the aromatic amino acid ammonia-lyase family catalyze the non-oxidative 
deamination of L-histidine, L-tyrosine and L-phenylalanine to yield the corresponding ,-
unsaturated acids and ammonia. The related aminomutase enyzmes catalyze the intramolecular 
2,3-migration of the amino group (Figure A-6).[61] Histidine ammonia-lyase (HAL), tyrosine 
ammonia-lyase (TAL) and phenylalanine ammonia-lyase (PAL) play diverse roles in the me-
tabolism of plants, microorganisms and animals, while aminomutase activity is markedly rare.[61] 
PAL activity is found in most plants and many fungi, where the production of (E)-cinnamate 
constitutes the first step of phenylalanine degradation. Cinnamic acid 23, in turn, is the precursor 
of many plant metabolites, including the flavonoids, the coumarins and lignin, the major con-
stituent of wood. The PAL enzymes of certain plants are also able to convert tyrosine to cou-
maric acid due to their secondary TAL activity.[61] A phenylalanine aminomutase (PAM) has 
been shown to supply (R)--phenylalanine as a precursor for the biosynthesis of the important 
anti-cancer drug Taxol in Taxus species.[62]  
HAL is present in prokaryotes and most higher animals. In bacteria, the HAL-catalyzed con-
version of L-histidine 17 to urocanate 18 constitutes the first step of the general "histidine utiliza-
tion" pathway (Figure A-7). Urocanate is further processed to imidazolonepropionate 25 by uro-
Figure A-6.  Reactions catalyzed by members of the
aromatic amino acid ammonia-lyase and aminomutase 
enzyme family. (A), HAL converts L-histidine 17 to uro-
canic acid 18; (B), TAL converts L-tyrosine 19 to cou-
maric acid 20, while TAM yields -tyrosine 21; (C), PAL 
converts L-phenylalanine 22 to cinnamic acid 23, and 
PAM produces -phenylalanine 24. 
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Figure A-7.  Degradation of L-histidine 17 to L-glutamate 28 via the "histidine utiliziation" pathway in the bacterium 
Pseudomonas putida. The involved enzymes are: HutH, histidine ammonia-lyase (HAL); HutU, urocanase; HutI, imi-
dazolonepropionate hydrolase; HutF, formiminoglutamate hydrolase; HutG, N-formylglutamate aminohydrolase. 
canase, followed by enzymatic hydrolysis to formiminoglutamate 26. Subsequent hydrolysis 
yields formylglutamate 27 and finally glutamate 28 (however, these two steps are combined into 
the elimination of formamide in some species). Genes encoding the required enzymes for this 
pathway are organized in the hut (histidine utilization) operon in many bacteria.[61] 
In contrast to histidine ammonia-lyase, PAL- and TAL-type enzymes are rare in bacteria – 
an observation that apparently reflects the general absence of phenylpropanoid-type metabolites 
in prokaryotes. The first bacterial PAL enzyme, EncP, was reported from Streptomyces mari-
timus, where it is involved in secondary metabolite biosynthesis (Figure A-8 A): Cinnamic acid 
23 produced by EncP is further transformed into cinnamoyl-CoA 29 by the CoA-Ligase EncH 
and is then degraded via a -oxidative route to yield benzoyl-CoA 30, which serves as starter 
unit for the biosynthesis of enterocin 31.[63,64] The involvement of another PAL in the biosynthe-
sis of isopropylstilbenes in Photorhabdus luminescens was recently demonstrated, and the corre-
sponding enzyme, StlA, was biochemically characterized.[65] Very recently, genomic mining has 
revealed the presence of putative PAL-encoding genes in the cyanobacteria Nostoc punctiforme 
and Anabaena variabilis, and the proposed activity of these enzymes has been biochemically 
confirmed.[66] The PAL-encoding genes in these species seem to be associated with hypothetical 
secondary metabolite biosynthetic gene clusters, but the role of cinnamic acid in the respective 
pathways is to date not clear. Phenylalanine aminomutase activity in bacteria appears to be as 
rare as in plants: the only report so far is related to the production of (S)--Phe by the enzyme 
AdmH during biosynthesis of the antibiotic Andrimid in Pantoea agglomerans.[67] 
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Enzymes of the ammonia-lyase family which use primarily (or exclusively) L-tyrosine as 
substrate are exceedingly rare in nature. Until recently, dedicated TAL enzymes were only 
known from Rhodobacter sphaeroides and Rhodobacter capsulatus.[68,69] In these species, p-
hydroxcinnamic acid (pHCA) 20 serves as the chromophoric group for the so-called "photo-
active yellow protein" (PYP). The covalent attachment of pHCA constitutes a post-translational 
modification which is essential for the function of these light sensor proteins. The kinetic char-
acterization of the two TALs from Rhodobacter has revealed that these enzymes additionally 
exhibit significant PAL activity.[68,69] 
Studies on the molecular basis of enediyne antibiotics formation in Streptomyces globisporus 
have highlighted the L-tyrosine 2,3-aminomutase (TAM) SgcC4 as a novel member of the am-
monia-lyase/aminomutase enzyme family (Figure A-8 B). SgcC4 converts L-tyrosine 19 prefer-
Figure A-8.  (A) The PAL enzyme EncP converts L-Phe 22 to cinnamic acid 23, which is further degraded to benzoyl-
CoA 30, a precursor for the biosynthesis of enterocin 31 by Streptomyces maritimus. (B) The tyrosine aminomutase 
SgcC4 from Streptomyces globisporus produces preferentially (S)--tyrosine 32, which undergoes further transforma-
tion into 3-Cl-4,5-(OH)2--Phe 33, a biosynthetic building block for the endiyne antitumor antibiotic C-1027 34. The 
ammonia-lyase and aminomutase-derived moieties, respectively, are highlighted by grey background color. 
 
  15 
A. Introduction 
entially to (S)--tyrosine 33, which is further modified by hydroxylating and chlorinating en-
zymes during enediyne biosynthesis.[43,70,71] A highly similar TAM enzyme, MdpC4, has re-
cently been shown to exert the analogous function to SgcC4 in the course of madurapeptin bio-
synthesis in the marine actinomycete Actinomadura madurae.[72]  
Taken together, the following picture evolves from the literature on the occurence and func-
tion of ammonia-lyase/aminomutase enzymes in nature: PAL represents an ubiquitous enzyme 
in plants, where it constitutes an important branching point between primary and secondary me-
tabolism. PALs are seldomly encountered in prokaryotes, but have been shown to supply cin-
namic acid precursors for a small number of secondary metabolite biosynthesis-related path-
ways. As an exceptionally rare enzyme, the singular role of TAL appears to be the provision of 
coumaric acid as a chromophore for the photoactive yellow proteins in Rhodobacter species. 
HAL, in contrast, occurs widely in bacteria and has an established function for histidine utiliza-
tion, catalyzing the first step of the general histidine degradation pathway. The rare aminomu-
tase enzymes PAM and TAM have been found associated with natural product biosynthetic 
routes in all instances reported to date, where they fulfill specialized roles as suppliers of -
amino acid building blocks. 
 
Discovery and characterization of new prokaryotic ammonia-lyase/aminomutase en-
zymes and elucidation of their roles in secondary metabolite biosynthesis. 
In the course of this thesis, a number of ammonia-lyase enzymes were characterized which 
exhibit uncommon catalytic properties, and/or play an unusual role in the metabolism of the re-
spective organism. These findings are summarized in the following. 
A) The tyrosine 2,3-aminoumutase CmdF from the myxobacterium C. crocatus was shown to 
produce preferentially (R)--tyrosine, in contrast to the previously known tyrosine aminomu-
tases, SgcC4 and MdpC4 from the enediyne biosynthetic pathways in S. globisporus und A. 
madurae, respectively (which predominantly yield (S)--tyrosine). Thus, CmdF is a novel 
member of the TAM enzyme family. Its product stereoselectivity matches the configuration 
of the -tyrosine building block incorporated into the chondramides (Figure A-9A).[44] The 
detailed biochemical characterization and mutational analysis of CmdF as well as attempts to 
alter its catalytic properties by genetic engineering are reported in chapter B-2.[45] These 
studies were extended towards the discovery and characterization of additional members of
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Figure A-9.  Novel members of the ammonia-lyase/aminomutase enzyme family which were characterized in this 
work, and their roles as suppliers of building blocks (grey background) for natural product biosynthesis. (A) TAMs 
from C. crocatus (CmdF) and Myxococcus (MfTAM, MxTAM), providing (R)--Tyr 34 for chondramide 35 biosynthesis 
and (S)--Tyr 36 for myxovalargin 37 biosynthesis, respectively. (B) Tyrosine ammonia-lyase from Saccharothrix 
espanaensis (Sam8) and its role in Saccharomicin biosynthesis. (C) Histidine ammonia-lyase from Stigmatella auran-
tiaca (HALSa) provides the urocanate starter unit 18 for the biosynthesis of imidacins. 
A. Introduction 
the emerging tyrosine aminomutase family from other bacterial sources. Genes encoding en-
zymes with TAM activity were cloned from two myxovalargin-producing Myxococcus spe-
cies and a strain of Cupriavidus metallidurans. The Myxococcus enzymes were heterolo-
gously expressed and could be shown to exhibit (S)--tyrosine stereoselectivity, consistent 
with their proposed function in supplying a (S)--tyrosine building block for myxovalargin 
biosynthesis (Figure A-9 A). TAM from Cupriavidus produced (R)--tyrosine, but the ki-
netic enzyme analysis revealed that this protein exhibits primarily TAL activity. Including 
the newly characterized proteins, the expanded tyrosine aminomutase enzyme family now 
comprises six representatives which differ markedly with respect to product stereospecificity 
and relative preference for aminomutase to ammonia-lyase activity. The increased availabil-
ity of TAM sequences enabled – for the first time – a phylogenetic analysis of tyrosine ami-
nomutases and led to the proposal of a new model for the evolution of this enzyme family 
(chapter B-2). 
B) A putative ammonia-lyase from the actinomycete Saccharothrix espanaensis, Sam8, was 
also recombinantly produced and biochemically characterized (chapter B-5).[73] Sam8 clearly 
preferred L-tyrosine over L-phenylalanine as substrate, and thus constitutes one of the few 
authentic TALs from bacteria. Notably, the characterization of Sam8 represents the first re-
port of a TAL from an actinomycete. Moreover, the suggested involvement of Sam8 in sec-
ondary metabolite biosynthesis in S. espanaensis is unprecedented in bacteria (Figure A-
9 B). Coumaric acid, the product of Sam8-catalyzed tyrosine conversion, is apparently ring-
hydroxylated to yield caffeic acid, which in turn is activated as caffeoyl-CoA prior to incor-
poration into the N-(dihydroxycinnamoyl) taurine aglycone of the saccharomicin antibiotics. 
C) Targeted inactivation of a gene encoding a putative histidine ammonia-lyase in Stigmatella 
aurantiaca Sg a15 (HALSa) led to the discovery of the imidacins, a novel class of myxobac-
terial secondary metabolites. Their biosynthesis depends on the supply of urocanic acid by 
HALSa (Figure A-9 C), revealing for the first time a non-standard role for histidine ammo-
nia-lyase in bacteria – namely, the involvement of HALSa in myxobacterial secondary me-
tabolism. This enzyme was heterologously expressed in E. coli and biochemically character-
ized (chapter B-4), and the pathway for the incorporation of urocanate into the newly 
identified metabolites was additionally delineated.[46] The incorporation of an urocanate 
building block has previously not been reported from any natural product. 
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On the structural and mechanistic basis for ammonia-lyase and aminomutase catalysis – 
implications for control of specificity and selectivity. 
A number of biochemical, molecular biological and structural studies have addressed ques-
tions related to the catalytic properties of aromatic amino acid ammonia-lyase and aminomutase 
enzymes. The activity of this enzyme family has been shown to rely on the uncommon pros-
thetic group 4-methylidene-imidazole-5-one (MIO), which results from the autocatalytic rear-
rangement of a signature Ala-Ser-Gly motif present in the protein (Figure A-10 A).[74] The exact 
role of MIO in ammonia-lyase and aminomutase chemistry has been controversially debated. 
Results from a study on histidine ammonia-lyase from Pseudomonas putida suggested the attack 
of the highly electrophilic MIO on the substrate imidazole ring, leading to activation of the non-
acidic -protons. Following the abstraction of a -proton by an enzymatic base, the reaction 
would proceed via the elimination of ammonia, rearomatization of the ring system to form the 
product (E)-urocanate, and regeneration of the MIO group (Figure A-10 B).[75] It has been pro-
Figure A-10.  (A) Self-modification of ammonia-lyase enzymes by condensation of residues from the internal tripepti-
dye Ala-Ser-Gly to form the MIO group. (B) Proposed catalytic mechanism for the conversion of L-histidine to uroca-
nate by HAL through a Friedel-Crafts-like attack of the electrophile MIO onto the substrate imidazole ring, followed by
abstraction of a -proton and elimination of ammonia. 
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posed that this Friedel-Crafts-like mechanism could similiarly apply to PAL, TAL and the ami-
nomutases.[61] 
An alternative mechanistic route requires the attack of MIO on the substrate amine, generat-
ing a covalent adduct that promotes the ,-elimination of ammonia from the amino acid. This 
mechanism is illustrated in Figure A-11 A for the TAM-catalyzed conversion of L-tyrosine to -
tyrosine, while Figure A-11 B depicts the Friedel-Crafts-type proposal for the same reaction.[76] 
Data from a recent crystallographic study on the tyrosine aminomutase SgcC4 from S. globis-
porus support the amino-adduct mechanism, because electron density continuous from the MIO 
group to the amino group of an substrate-analogous inhibitor has been detected in the active site 
of SgcC4 (Figure A-11 C).[77] Either way, the aminomutase reaction is thought to proceed via a 
para-hydroxycinnamate (pHCA) intermediate. Consistent with this assumption, it has been ob-
served that SgcC4 exhibits significant TAL activity as a side reaction.[78] In the ammonia-lyase 
reaction pathway, the pHCA intermediate and ammonia are released, while retention of ammo-
nia in the active site of aminomutases facilitates a subsequent 1,4-addition between the enzyme-
Figure A-11.  (A, B) Two alternative mechanistic proposals for MIO-based tyrosine aminomutases. (C) Structure of 
SgcC4 bound to the substrate analogue ,-difluoro--tyrosine (left), and interactions between enzyme and bound 
substrate analogue in the active-site region (right). Red, MIO group; black, substrate analogue; blue, amino acid resi-
dues from SgcC4. Adapted from [77] with permission. 
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bound intermediates, affording the -amino acid as the end product. The orientation of the 
pHCA intermediate in the active-site pocket determines the facial selectivity of ammonia addi-
tion, and thus in principle, both enantiomers of the -amino acid product may result.[77] Notably, 
the known tyrosine aminomutases SgcC4 and MdpC4 from the enediyne biosynthetic pathways 
have been demonstrated to produce preferentially (S)--tyrosine, while the newly reported 
CmdF from C. crocatus primarily yields (R)--tyrosine.[44] Moreover, two additional tyrosine 
aminomutases from Myxococcus species exhibit (S)--tyrosine stereoselectivity, but a new en-
zyme from Cupriavidus affords preferentially (R)--tyrosine.[45] These findings raise questions 
concerning the evolution of stereocontrol in the TAM enzyme family. 
The availability of crystallographic data for HAL, PAL, TAL and TAM proteins has helped 
to shed light on the correlation between structural features and catalytic properties of these en-
zymes. Based on the combined results from a structural study and site-directed mutagenesis ex-
periments, amino acid residues in the active site of HAL from P. putida with an implication in 
substrate binding and catalysis have been identified.[75] One highly conserved glutamic acid 
residue, Glu414, has been shown to be useful as a predicitve tool, allowing to distinguish HAL 
from both TAL and PAL through the in-silico analysis of a candidate protein sequence.[79] Very 
recently, key amino acids which control substrate selectivity have also been reported for TAL 
from Rhodobacter.[80] In particular, one conserved histidine residue, His89, has been found to 
direct substrate recognition. When this position in the amino acid sequence was changed to 
phenylalanine, the enzyme exhibited efficient PAL activity, identifying His89 as a selectivity 
switch.[66] 
It has been suggested that these substrate selectivity principles could similarly apply to the 
aminomutases - a notion that is apparently supported by the recent crystal structure of the tyro-
sine aminomtase SgcC4.[77] However, it has to be pointed out that enzymes of the TAM family 
have not been extensively studied by molecular biological approaches prior to this work. Thus, 
the determinants of product specificity (i.e., what makes the enzymes aminomutases versus am-
monia-lyases) and stereoselectivity remain to be elucidated. Such information constitutes an im-
portant prerequisite for future attempts to manipulate rationally the catalytic properties of ami-
nomutases for various biotechnological applications. Therefore, the heterologous expression of 
new tyrosine aminomutases was carried out to enable their biochemical characterization. Fur-
thermore, site-directed mutagenesis of the tyrosine aminomutase CmdF from C. crocatus was 
performed, aiming at the exploration of structure-function relationships for conserved sequence 
motifs found in the tyrosine aminomutase enzymes (chapter B-2). 
A. Introduction 
6.  A diversity-oriented approach for the analysis of myxobacterial secondary me-
tabolite production patterns by high-resolution mass spectrometry  
The myxobacteria as a group have been demonstrated to produce a wide variety of secondary 
metabolites, but the degree of metabolic diversity that can be found within a single species has 
not been systematically investigated. Strains belonging to certain myxobacterial species, e.g. 
Sorangium cellulosum, seem to exhibit low intraspecific overlap in their secondary metabolite 
profiles and yield at the same time a high number of natural products not known from other 
(myxobacterial) genera.[18] In contrast, strains of the species Myxococcus xanthus have been 
shown to date to produce only eight compound classes – five of which have been reported from 
other myxobacteria as well (Figure A-12, 38-42),[81-85] while the three remaining structures are 
highly similar or even identical to compounds previously identified from members of the Actin-
omycetales (Figure A-12, 43-45).[86-88] These findings are apparently not in agreement with the 
genetic potential of M. xanthus for the production of secondary metabolites. Genomic mining 
Figure A-12.  Overview of natural products discovered to date from the species Myxococcus xanthus. 38, myxovire-
scin; 39, DKxanthene; 40, myxochromide A; 41, myxalamide; 42, myxochelin; 43, saframycin; 44, althiomycin; 45, 
cittilin. 
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has revealed at least 18 gene clusters encoding secondary metabolite assembly lines of the PKS-, 
NRPS- or mixed PKS/NRPS-type in the genome of the model strain M. xanthus DK1622, sug-
gesting that this strain should produce a substantial number of secondary metabolites.[40] How-
ever, to date only five known M. xanthus metabolites have been identified in extracts from 
DK1622 cultivations (Figure A-12, 38-42). 
To evaluate further the secondary metabolite diversity in M. xanthus, a considerable number 
of M. xanthus strains isolated from locations worldwide was screened. This study aimed at de-
termining whether the metabolic inventory of this species, as observable under laboratory condi-
tions, is largely present in DK1622 or whether there is significant potential for novel compound 
discoveries in other strains. Liquid chromatography-coupled mass spectrometry (LC-MS) was 
considered the appropriate analytical technique for this purpose, as it can in principle capture a 
highly diverse range of chemical compounds and enables the detection of even minor constitu-
ents in a given sample. Thus, a screening platform consisting of fast chromatographic separation 
(UPLC), electrospray ioniaztion (ESI), and high-resolution (HR) time-of-flight mass spectrome-
try (ToF-MS) was implemented and is briefly described in the following.  
Data from HR LC-MS measurements can be conveniently employed for compound identifi-
cation in highly complex mixtures, based on the combined evaluation of retention time, accurate 
m/z value, and isotope pattern (Figure A-13). These properties also form the basis for a targeted 
Figure A-13.  Implementation of LC-coupled high-resolution mass spectrometry for compound identification and tar-
get screening, using both mass accuracy and isotope pattern information. This example illustrates the identification of 
cittilin A in extracts from a weak producer (note the different intensity scales of base peak chromatogram (BPC) and
extracted ion chromatogram (EIC)). Adapted from [ref]. 
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screening procedure, which is applied to HR LC-MS measurements in order to quickly gain an 
overview of known compounds present in a sample. This overview in turn greatly facilitates 
dereplication.[89] The required input for a high-resolution target screening database is the mo-
lecular formula plus the retention time determined under standardized chromatographic condi-
tions. In a first step, accurate m/z values for pseudomolecular ions, [M+H]+, are calculated from 
the molecular formulae and extracted ion chromatograms (EICs) are created in the dataset under 
investigation, using a low m/z tolerance (usually below 5 mDa). A chromatographic peak is sub-
sequently detected by a peakfinder algorithm, and mass spectra found in the respective peak are 
averaged and compared to the theoretical spectrum, derived from the molecular formula (Figure 
A-13). Finally, the deviation of mass positions is evaluated and a match factor, the so-called 
"sigma value" (, is calculated based on the deviations of measured signal intensities from the 
theoretical isotope pattern. This approach, sometimes termed "SigmaFit", also enables the gen-
eration of molecular formulae for unknown compounds with increased confidence, in compari-
son to the evaluation of precise m/z values only.[90] 
Data from high-resolution LC-MS measurements are also suitable for processing by an in-
novative "find-all-compounds" approach, which can effectively reduce the complexity of LC-
Figure A-14.  Illustration of a pre-processing approach for high-resolution LC-MS data which implements a com-
pound-finding algorithm. Isotope peaks are identified by correlation analysis, tolerances are applied in the time- and 
m/z-domain (here,  Ret. = 20 s and  m/z = 10 mDa), and all signals that originate from a parent ion are subse-
quently merged into one "compound bucket". 
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MS datasets prior to their interpretation by statistical methods. Briefly, the underlying idea is to 
differentiate all compounds with a chromatographic elution profile from randomly dispersed 
background noise (Figure A-14). All m/z signals that originate from one compound, including 
isotope peaks and multiply charged ions (if present), are merged into a "compound bucket" 
which is characterized by one noise-free mass spectrum, preserving the retention time as well as 
chromatographic peak area and intensity as additional information. It is expected that most of 
the putative compounds defined by this "compound-based bucketing" approach represent actual 
chemical species in the sample. Notably, the obtained list of reported compounds does also con-
tain unknowns, which would not have been revealed by targeted screening (since their presence 
in a sample was not anticipated). 
Using computational methods, the comparative analysis of untreated LC-MS data derived 
from different samples is usually unfeasible for a number of reasons, including the presence of a 
considerable degree of chemical noise and retention time variation among sample runs. Compar-
ing the complement of compounds found by the above-described approach thus constitutes a 
practical alternative to the direct comparison of raw LC-MS data, when aiming at the discovery 
of significant differences between samples. Furthermore, the "compound buckets" may be di-
rectly used in the calculation of a statistical model for the classification of samples according to 
their metabolite profiles. One established method from the metabolomics field which was used 
in this work is "Principal Component Analysis" (PCA). PCA is an unsupervised pattern recogni-
tion technique which creates an overview of a multivariate dataset and thereby reveals groups of 
observations, trends and outliers.[91] In the context of LC-MS, PCA is applied as a statistical fil-
ter which highlights compounds responsible for significant variance in a set of samples.[92] 
The combined use of target screening and compound-based PCA for the analysis of variation 
among myxobacterial production patterns, utilizing data from high-resolution ESI-TOF meas-
urements, is described in more detail in chapter B-7.[47] These techniques were also employed to 
investigate the metabolite profiles from 98. M. xanthus strains that originate from locations 
worldwide (chapter B-6).[48] This study revealed a strikingly high level of intraspecific diversity 
in the M. xanthus secondary metabolome. A considerable number of non-ubiquitous candidate 
compounds was reported, greatly exceeding the small number of secondary metabolites previ-
ously known to derive from M. xanthus. Thus, M. xanthus should be regarded as a promising 
source of natural products. The implementation of high-resolution LC-MS-based methods within 
a general analytical framework for diversity-oriented mining of the myxobacterial secondary 
metabolite inventory is discussed in chapter B-8.[49] 
A. Introduction 
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The imidacins constitute a novel class of secondary metabolites produced in minute quantities by the 
myxobacterium Stigmatella aurantiaca Sg a15. They were discovered after inactivation of a gene en-
coding a histidine ammonium-lyase by comparative metabolite profiling. Structural elucidation of the 
imidacins revealed a unique fatty acid-like scaffold, consisting of an imidazole-acryl moiety linked via 
a linear alkyl chain of variable length to a carboxy group. In addition, some of these compounds ex-
hibit a rare cyclopropane ring. The highly uncommon imidazole-acryl substructure could be shown to 
stem directly from urocanic acid, which in turn is derived from L-histidine. The histidine ammonium-
lyase enzyme responsible for this transformation was cloned from Sg a15 and characterized biochemi-
cally. The results of targeted gene inactivation experiments and feeding studies, in combination with 
the identification of further candidate genes through screening of a transposon library, allowed to 
eventually identify the imidacin biosynthetic gene cluster and deduce a model for imidacin biosynthe-
sis. The proposed biosynthetic route starts with the activation of urocanate, representing a building 
block not previously reported from any natural product. Extension by chain elongation starting from 
carrier protein bound urocanate is subsequently performed by an iterative type I polyketide synthase, 
and late biosynthetic steps include the introduction of a cyclopropane moiety by enzymatic methylena-
tion of an unsaturated intermediate. Genes involved in imidacin biosynthesis were found distributed 
on at least three chromosomal loci in the S. aurantiaca Sg a15 genome. Thus, the data presented in this 
study uncover an intriguing interplay of diverse biosynthetic functionalities commonly associated with 
unrelated prokaryotic metabolic pathways. 
 
 
Myxobacteria are soil-living organisms that exhibit 
a complex lifestyle, which includes coordinated 
swarming on surfaces, cooperative feeding on bio-
logical macromolecules or even live bacteria, and 
the development of multicellular fruiting bodies un-
der starvation conditions.[1] Myxobacteria have also 
attracted attention as a rich source of natural prod-
ucts with diverse structures and biological activi-
ties.[2] The species Stigmatella aurantiaca, for ex-
ample, is a well-established myxobacterial 
multiproducer of secondary metabolites. Two S. au-
rantiaca strains have been especially in the focus of 
research: strain Sg a15 produces the antibacterial 
myxalamids, the potent electron-transport inhibitor 
stigmatellin, the iron-chelating myxochelins as well 
as the alkaloid aurachin and a range of volatile com-
pounds,[3-6] while the ACE-inhibitor myxochromid, 
the antibiotics myxothiazol and aurafuron, plus the 
DKxanthenes and dawenol have been reported from 
S. aurantiaca DW4/3-1.[7-11] 
Most of these compounds originate from bio-
synthetic machinery consisting of polyketide syn-
thases (PKS) and non-ribosomal peptide synthetases 
(NPRS), which act as enzymatic assembly lines by 
catalyzing the stepwise condensation of a starter unit 
with small monomeric building blocks, yielding 
more complex chemical structures. Polyketide syn-
thases of a particular architecture, termed ‘type I’, 
exhibit a multimodular organization where each 
module performs one cycle of chain extension.[12] 
The minimum module contains three functionalities: 
the acyltransferase (AT) domain selects an extender 
  4. Imidacin structure and biosynthesis 
unit, usually the activated form of a short-chain di-
carboxylic acid such as malonyl-CoA, and transfers 
it onto the acyl carrier protein (ACP) domain within 
the same module. The ketosynthase domain (KS) 
subsequently deacarboxylates the extender unit and 
performs a Claisen-like condensation with the grow-
ing polyketide chain bound to the multienzyme. Ad-
ditional domains are often integrated into a module 
and contribute to the structural diversity of PKS-
derived metabolites: a ketoreductase (KR) domain 
reduces the -keto group to an alcohol, a dehydra-
tase domain (DH) then catalyzes the elimination of 
water to form an ,-double bond, and finally an 
enoylreductase (ER) domain may reduce this double 
bond, resulting in a methylene moiety. In textbook 
bacterial PKS biosynthetic pathways, each module 
in the enzymatic assembly line is used only once, 
and the order of modules and arrangement of do-
mains contained in these modules therefore corre-
spond to the chemical structure of the polyketide 
product – an observation that has been termed the 
‘colinearity rule’.[12] In the past years, the molecular 
basis for the formation of many myxobacterial natu-
ral products, including several secondary metabo-
lites from S. aurantiaca, has been investigated in 
detail.[8,13-17] These studies have frequently revealed 
unexpected genetic organizations of biosynthetic 
pathways and surprising biosynthetic features that 
challenge traditional textbook biosynthetic logic, 
such as the iterative use or the complete skipping of 
modules and the incorporation of unusual building 
blocks and starter units.[18] 
The starter units for PKS or NRPS biosynthesis 
are mostly recruited from primary metabolism, e.g. 
short-chain carboxylic acids or amino acids, and are 
usually activated as CoA-thioesters or (amino-)acyl 
adenylates prior to their loading onto the biosyn-
thetic assembly line. However, rather uncommon 
building blocks may also be generated by dedicated 
enzymes and furnish specific pathways. One class of 
enzymes that has occasionally been described to 
fulfill this role are the aromatic amino acid ammo-
nium-lyases.[19] These enzymes generally catalyze 
the non-oxidative deamination of L-tyrosine, L-
phenylalanine or L-histidine to yield the correspond-
ing ,-unsaturated carboxylic acid. Phenylalanine 
ammonium-lyase (PAL), for example, has been 
shown to deliver cinnamic acid as a precursor for 
stilbene biosynthesis in P. luminescens and is in-
volved in starter unit biogenesis in the enterocin bio-
synthetic pathway from S. maritimus.[20,21] Tyrosine 
ammonium-lyase (TAL) has been demonstrated to 
supply p-hydroxycinnamic acid for the formation of 
saccharomicin antibiotics in the actinomycete S. es-
panaensis.[22] In contrast to PAL and TAL which 
represent rare activities in bacteria, a gene encoding 
a histidine ammonium-lyase (HAL) can be found in 
the genomes of many species. HAL is commonly 
associated with prokaryotic primary metabolism, 
where it catalyzes the first step in the general his-
tidine degradation pathway.[19] 
In our current study we report, to the best of our 
knowledge for the first time, the involvement of 
HAL in secondary metabolite biosynthesis. Follow-
ing the identification of urocanic acid, the product of 
HAL-catalyzed histidine degradation, as the starter 
unit for two novel natural products with intriguing 
structural features, we set out to elucidate their 
structures and additionally delineate the biosynthetic 
pathway for their formation in S. aurantiaca Sg a15. 
Figure 1. (A) Portion of an ClustalW alignment of pro-
karyotic ammonium-lyase protein sequences. Upper part, 
histidine ammonium-lyase enzymes (HAL): HALSa (S. 
aurantiaca Sg a15), MxHAL (M. xanthus), ScHAL (S. cel-
lulosum), PpHAL (P. putida), BsHAL (B. subtilis). Lower 
part, enzymes that use phenylalanine (PAL) or tyrosine 
(TAL, TAM) as substrates: PlPAL (P. luminescens), 
NpPAL (N. punctiforme), SeTAL (S. espanaensis), 
CmTAM (C. crocatus). The semi-conserved residue high-
lighted with a triangle is commonly used to distinguish 
HAL enzymes from ammonium-lyases which use alterna-
tive substrates. (B) Localization of genes encoding func-
tions for the general histidine degradation pathway in the 
genomes of P. putida (a), M. xanthus (b) and S. cellulo-
sum (c). Numbers in parentheses are distances in million
basepairs. Grey rectangles adjacent to genes are promo-
tor regions in P. putida (a). HAL is often referred to as
HutH (grey arrows). See also Figure 2 and legend text. 
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Results 
Biochemical characterization of the histidine 
ammonium-lyase HALSa 
In the course of previous investigations on the 
molecular basis of myxalamid formation in S. au-
rantiaca Sg a15 an open reading frame 1527 bp in 
size was identified, the deduced amino acid se-
quence of which exhibits similarity to many his-
tidine ammonium-lyase (HAL) proteins from vari-
ous bacterial sources.[14] Sequence comparison 
revealed the putative HAL from Sg a15 (HALSa) as 
a homolog of MxHAL from Myxococcus xanthus 
DK1622 (MXAN_3465, 86% identity, 93% similar-
ity on the amino acid level), which was recently 
shown to be responsible for urocanic acid produc-
tion in this myxobacterium.[23] HALSa is also similar 
to biochemically characterized HAL enzymes from 
Bacillus subtilis (HutH, 46% / 64%) and Pseudomo-
nas putida (HutH, 45% / 61%). Furthermore, a glu-
tamic acid residue is found at position 415 in HALSa 
which is strictly conserved in ammonium-lyase en-
zymes that accept histidine as substrate (Fig. 1A). 
This amino acid is commonly used as a predictive 
tool to distinguish HAL from members of the am-
monium-lyase enzyme family that act on phenyla-
lanine (PAL) or tyrosine (TAL).[20,22,24] 
HAL enzymes catalyze the elimination of am-
monia from L-histidine to yield trans-urocanic acid 
(Fig. 2).[19] To confirm that HALSa can perform this 
function, the protein was overexpressed in E. coli 
BL21 as a C-terminal fusion with glutathione S-
transferase, similar to a previously described proce-
dure.[25] Purification of HALSa (509 aa, calculated 
Mr, 56309 Da) was achieved by glutathione affinity 
chromatography, followed by on-column cleavage 
using PreScission protease (Fig. 3A). The purified 
enzyme was then incubated with L-tyrosine, L-
phenylalanine and L-histidine in order to assay for 
ammonium-lyase activity. The biochemical charac-
terization of recombinant HALSa (Fig. 3B) revealed 
that it can efficiently convert L-histidine to urocanic 
acid, while no turnover with alternative substrates 
was observed. The determined kcat (0.1 s-1) and KM 
(0.37 mM) values are significantly lower when 
compared to HutH from P. putida (86 s-1 and 3.9 
mM, respectively),[26] but are found within the range 
of kinetic parameters reported for other enzymes of 
the ammonium-lyase family.[20] The highest activity, 
as judged by relative initial rates of product forma-
tion, was observed at pH ~9 (Fig. 3C), which is 
typical for ammonium-lyase-type enzymes. Thus, 
HALSa indeed is a histidine ammonium-lyase, as 
anticipated on the basis of sequence similarity. 
 
Inactivation of HALSa reveals its unusual role in 
secondary metabolism of Sg a15 
HAL is present in many bacterial species,[19] 
since it catalyzes the first step of the general degra-
dation pathway from L-histidine to L-glutamate (Fig. 
2). It is usually encoded within a “histidine utiliza-
tion” (hut) operon, together with enzymes that carry 
out further chemical transformations on urocanate, 
the product of the HAL reaction (Fig. 1B). The 
HALSa-encoding gene is apparently not part of such 
an operon in S. aurantiaca Sg a15, as judged by its 
position next to the myxalamide biosynthesis gene 
Figure 2. Chemical transformations during the degrada-
tion pathway from L-histidine via urocanic acid to L-
glutamic acid. The involved enzymes are: HutH, histidine
ammonium-lyase EC 4.3.1.3 (HAL); HutU, urocanase EC
4.2.1.49 ; HutI, EC 3.5.2.7; HutF, EC 3.5.3.8; HutG, EC
3.5.1.68. Urocanic acid constitutes the branching point
into the biosynthesis of two novel metabolites in S. auran-
tiaca Sg a15. 
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cluster.[14] Furthermore, searching for typical his-
tidine utilization genes in the genomes of two se-
quenced myxobacterial model strains, M. xanthus 
DK1622 and S. cellulosum So ce56, indicated that 
putative hut genes are distributed over distant loca-
tions on their chromosomes (Fig. 1B). Thus, it 
seems that a genetically disintegrated histidine utili-
zation pathway is a common characteristic of vari-
ous myxobacterial species. This observation 
prompted us to investigate the function of HALSa by 
targeted gene inactivation, which was achieved by a 
previously established method of plasmid insertion 
mediated through single-crossover homologous re-
combination (see experimental procedures).[27] The 
resulting kanamycin-resistant mutant strain 
Sga15HAL- no longer produced urocanic acid, as 
confirmed by GC-MS analysis (supplemental Fig. 
S1). Comprehensive HPLC-DAD-MS analysis of 
extracts derived from liquid cultivations of wildtype 
Sg a15 and Sga15HAL- highlighted the absence of 
two signals with 319 m/z and 347 m/z in the 
Sga15HAL- extract (Fig. 4, traces A and B). On the 
basis of high-resolution ESI-MS measurements, the 
molecular formulae C19H30N2O2 (calculated m/z 
[M+H]+, 319.2380 Da; measured, 319.2374 Da) and 
C21H34N2O2 (calculated m/z [M+H]+, 347.2693 Da; 
measured, 347.2685 Da) could be assigned to these 
compounds (in the following referred to as ‘c319’ 
and ‘c347’ and named imidacin A1 and A2 later) 
with high confidence. These molecular compositions 
did not match any known myxobaterial natural 
product from our in-house compound database, and 
no plausible hits were encountered when searching 
multiple publicly accessible compound databases. 
The production of these two metabolites by the 
Sga15HAL- mutant was restored to wildtype level 
through feeding of (E)-urocanic acid to the liquid 
culture (Fig. 4, trace C). This finding suggests that 
their formation depends on the availability of either 
urocanic acid, or another downstream intermediate 
from the histidine degradation pathway (Fig. 2) as a 
potential bioynthetic precursor. Wildtype Sg a15 
cultures were also supplemented with urocanic acid 
and with histidine, but neither addition did increase 
production yields of the two novel metabolites (Fig. 
7C). 
Figure 3. (A) SDS-PAGE to visualize the recombinant production in E. coli BL21 and purification of HALSa (calculated 
Mr, ~56 kDa). (B) Non-linear regression of observed intial velocities for the conversion of L-histidine to urocanic acid by 
HALSa, using substrate concentrations in the range from 50 µM to 4 mM. (C) pH-dependency of HALSa-catalyzed uro-
canic acid formation. 
 
Inactivation of urocanase does not impair pro-
duction of the novel metabolites 
We next aimed at disrupting the gene hutU, en-
coding an urocanase (HutU) which catalyzes the 
next reaction in the histidine degradation pathway, 
following the initial conversion of histidine to uro-
canic acid. This inactivation experiment was ex-
pected to enable the discrimination between uro-
canic acid and its further degradation products as 
possible precursors for the newly identified metabo-
lites (Fig. 2). Since genome sequence information is 
not available for S. aurantiaca Sg a15, degenerate 
primers were employed for the PCR-amplification 
of a 682-bp fragment from chromosomal DNA of 
that strain (see methods). This fragment was cloned 
into the pCR2.1Topo vector, and sequence analysis 
revealed convincing similarity to hutU genes from 
several organisms. The obtained plasmid pTOPO-
hutU was used for insertional gene inactivation in 
Sg a15. HPLC-MS analysis of the resulting mutant 
strain Sga15HutU- showed unambiguously that the 
compounds with 319 m/z and 347 m/z were still pro-
duced (Fig. 4 trace D). Thus, it could be concluded 
that urocanic acid is recruited from the histidine 
degradation pathway for the biosynthesis of two 
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novel metabolites by Sg a15. Production yields from 
the Sga15HutU- mutant were marginally increased 
in comparison to the cultivation of wildtype Sg a15, 
but did not rise further upon addition of histidine or 
urocanic acid to the culture (Fig. 7c). 
 
Complementation of Sga15HAL- with 13C6-
urocanic acid 
The outcome of the hutU inactivation experi-
ment helped to define the branching point from the 
histidine degradation pathway, into an as yet un-
characterized biosynthetic route resulting in forma-
tion of c319 and c347, at the level of urocanic acid. 
Consequently, we set out to elaborate further on the 
fate of the proposed urocanate building block. We 
reasoned that feeding of 13C-urocanic acid should be 
informative for determining whether the complete 
carbon scaffold, or a different molecule resulting 
from further transformation of urocanic acid offside 
the histidine degradation pathway, is actually incor-
porated into the novel metabolites. As uniformly 
13C-labeled urocanic acid was not commercially 
available, recombinant HALSa was used for the in-
vitro conversion of 13C6-L-histidine to 13C6-urocanic 
acid. The Sga15HAL- mutant was chosen for the 
subsequent feeding experiment, since it conven-
iently allowed for the incorporation of 13C6-
urocanate without intrinsic background that would 
result from the HAL-catalyzed conversion of non-
labelled histidine in the wildtype strain. Extracts 
from a cultivation of Sga15HAL- in the presence of 
~1 mM 13C6-urocanic acid were analyzed by HPLC-
Figure 4. HPLC-MS analysis of extracts from cultivations of S. aurantiaca Sg a15 and selected mutants constructed in 
this study. (A) wildtype Sg a15, (B) HALSa inactivation mutant Sga15HAL-, (C) complementation of Sga15HAL- with uro-
canic acid, (D) urocanase knockout strain Sga15HutU-, (E) strain Sga15-A with inactivated imd1, (F) strain Sga15-orf7 
with inactivated orf7, (G) Sga15-npt mutant strain, harbouring the npt promotor sequence inserted upstream of imd2. 
See text for more details. Peaks at 16.7 min and 18.5 min represent imidacins A1 and A2 (compounds c319 and c347) 
with 319 m/z and 347 m/z, respectively. Basepeak chromatograms (BPC) in the mass range 300–400 m/z are shown. 
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coupled positive ESI-iontrap mass spectrometry. 
Signals with 325 m/z and 353 m/z were detected at 
the same retention times that were previously ob-
served for the non-labelled compounds with 319 m/z 
and 347 m/z, and the corresponding ions were sub-
jected to multiple stages of collisionally-induced 
dissociation (CID). This analysis revealed unambig-
ously that all carbon atoms from urocanic acid are 
incorporated into the novel metabolites, due to the 
observed mass shifts of +6 Da (Fig. 5). Furthermore, 
the fragmentation pattern permitted a preliminary 
assessment of putative compound structures. Taking 
into account the proposed elemental compositions, it 
could be estimated that the novel compounds are 
approximately linear molecules and consist of a 
terminal urocanic acid-derived substructure, linked 
to a carboxylate group via an alkyl chain bearing 
further modifications. Disappointingly, an initial 
isolation attempt from the supernatants of 10 L of S. 
aurantiaca Sg a15 batch cultures yielded only mi-
crogram quantities of these compounds. 
 
Identification of biosynthetic candidate genes and 
inactivation experiments 
Due to the limited availability of material, a 
comprehensive structure proposal for the novel me-
tabolites could not be made at an early stage, and 
consequently genes and enzymes possibly involved 
in their biosynthesis could not be readily inferred. 
Therefore, a library of kanamycin-resistant Sg a15 
mutants, harboring random chromosomal insertions 
of the mariner-based transposon plasmid pMyco-
Mar,[16] was screened in order to identify genes with 
functions in the biosynthesis of the urocanate-
derived metabolites. HPLC-MS analysis of super-
natants from 1,920 mutants highlighted one clone, 
designated Sga15-29F10, which lacked formation of 
the target compounds with 319 m/z and 347 m/z. 
Production of these was not restored by feeding of 
urocanic acid to a Sga15-29F10 culture, indicating 
that a genetic locus different from HALSa was af-
fected by insertion of the transposable element. 
Plasmid recovery was carried out using SmaI-
digested chromosomal DNA from strain Sga15-
29F10 (see methods), and sequencing of plasmids 
p29F10 and p29F10Sma uncovered a 13 kbp stretch 
of sequence centered around the transposase inser-
tion site (Fig. 6). The deduced amino acid sequences 
of genes located close to the termini of this region 
showed similarity to a partial KS domain and an 
α,-hydrolase, respectively, and these genes were 
inactivated by plasmid insertion. The resulting mu-
tant strains Sga15in2 and Sga15in3 were both defi-
cient in production of the urocanate metabolites, as 
confirmed by HPLC-MS analysis (data not shown). 
PCR-screening of a pooled Sg a15 cosmid library 
(see methods) revealed two overlapping cosmids, 
Cos13F7 and Cos11D1, which contained the previ-
ously identified 13-kbp stretch of sequence, and fur-
ther sequence information was acquired from these 
cosmids by primer walking. 
Figure 5. Incorporation of 13C6-urocanic acid into imidacin A1. Multiple stage tandem-MS analyses (MS2, MS3) of ex-
tracts form a control cultivation of strain Sga15HAL- (left side) and a culture suplemented with 13C6-urocanic acid (right 
side) are shown. Incorporation of the complete carbon skeleton of urocanic acid is evident from the observed mass shifts
of +6 Da. 
The arrangement of predicted open reading 
frames in the sequenced region spanning a total of 
46 kbp is depicted in Figure 6, and the results of the 
in-silico analysis  are  summarized  in  Table 1.  The 
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Table 1. Genes and proteins located in the sequenced region. The position in the DNA sequence and the length of de-
duced proteins and their proposed functions are given. The nucleotide sequence information determined in this study
was deposited with EMBL (accession no. xxxxxxx). Proteins were designated as "hypothetical proteins" if no biochemi-
cally characterized representative with convincing similarity could be found by BLAST searching, using the deduced
amino acid sequence as query. "STIAU" numbering relates to annotated genes in the Stigmatella aurantiaca DW4/3-1 
draft genome sequence (GenBank accession no. AAMD00000000). 
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  4. Imidacin structure and biosynthesis 
putative open reading frames imd2, imd3, imd1 plus 
the three genes located in between the latter two are 
all transcribed in the same direction and constitute 
an apparent operon, flanked by intergenic gaps with 
a length of 1824 bp (upstream) and 1517 bp (down-
stream), respectively. These sequence segments ex-
hibit an unusually low average GC-content – e.g., 
only 54 % are calculated for the upstream gap, and 
searching for proteins possibly encoded in this re-
gion provided evidence for the presence of a trun-
cated transposase gene. The gene products of imd1, 
imd2, imd3 and orf7 harbor catalytic domains com-
monly associated with PKS-directed biosynthesis 
(Table 1 and Fig. 6). Inactivation of imd1 – encod-
ing a protein with predicted integral adenylation (A), 
enoylreductase (ER), acyl carrier-protein (ACP) and 
ketosynthase (KS) domains – by single-crossover 
plasmid insertion yielded mutant Sga15-A. This mu-
tant did not produce the urocanate-derived metabo-
lites, as revealed by HPLC-MS analysis (Fig. 4, 
trace E). In contrast, the inactivation of orf7, encod-
ing a putative CoA-ligase (CL) and a ketosynthase 
(KS) domain, gave rise to a mutant with unchanged 
metabolite production pattern when compared to the 
wildtype (Fig. 4, trace F). Similarly, the HPLC-MS 
analysis of extracts from mutants Sga15-stpk and 
Sga15-sig54 revealed that production yields for the 
urocanate-derived metabolites were not significantly 
altered in these knockout strains (Table 1, Fig. 7C). 
The deduced amino acid sequences of three pu-
tative genes interspersed in between imd3 and imd1 
exhibit similarity to members of the SAM-binding 
enzyme superfamily (imd4), to proteins with a gen-
eral ,-hydrolase fold including enzymes with es-
terase activity (imd5), and to proteins of undefined 
function which possess leucine-rich repeat motifs as 
a common feature (orf3) (Fig. 6, Table 1). The in-
tergenic distance between orf3 and imd1 may indi-
cate the presence of a promoter in this region. Lo-
cated downstream of imd1, but transcribed in the 
opposite direction, orf4 encodes a hypothetical YD-
repeat containing protein that is unlikely to be in-
volved in any biosynthetic transformation.  
When comparing the predicted gene products in 
the sequenced 46-kbp region from Sg a15 to the 
draft genome sequence of S. aurantiaca DW4/3-
1,[28] it is evident that homologs of orf5 to orf13 plus 
orf1 and orf2 exist in that strain (Table 1). Further-
more, the similar arrangement in DW4/3-1 of genes 
corresponding to orf5 to orf13 from Sg a15 indicates 
local synteny between the genomes of both strains. 
Notably, genes with similarity to imd1–imd3 could 
not be identified, consistent with the fact that strain 
DW4/3-1 does not produce the urocanate-derived 
metabolites (data not shown). The inactivation ex-
periments described above confirm that the proteins 
encoded within this operon are essential for the bio-
synthesis of the novel urocanate-derived compounds 
in Sg a15. Thus, the biosynthetic genes are split into 
at least two chromosomal loci: one of these is the 
halsa gene, which is responsible for providing the 
urocanate precursor, and the second locus is the re-
gion encoding PKS-like biosynthetic machinery that 
was identified by the transposon mutagenesis ap-
proach. 
 
Increased product yield via promoter insertion 
Having identified a set of candidate genes for 
the biosynthesis of compounds c319 and c347, we 
aimed at using this information in order to geneti-
cally engineer S. aurantiaca Sg a15 for increased 
production of the novel metabolites. We hoped to 
thereby facilitate the isolation of sufficient material 
for further structural characterization because previ-
ous studies indicated the successful application of 
this strategy: Insertion of the npt promoter in front 
of the myxochromide biosynthetic gene cluster of 
M. xanthus DK1622 increased production approxi-
mately 50 fold (Silke C. Wenzel and R.M., unpub-
lished results). 
Figure 6. Putative open reading frames and proposed functions encoded in a 46-kbp sequence region covered by plas-
mid p29F10Sma and comsids Cos13F7 and Cos11D1. Genes marked with crosses have been inactivated by single-
crossover plasmid insertion. The black triangle highlights the insertion site of the mariner-based transposon plasmid 
pMycoMar. Genes between imd2 and imd1 form an apparent operon. See results section for more information. 
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Figure 7. (A) Time course for the production of c319 and 347 by S. aurantiaca Sg a15. Dashed line, relative concentra-
tions as determined by HPLC-MS analysis, summarized for both metabolites (right axis). Solid curve, bacterial growth
followed by monitoring absorption at 600 nm (left axis). Results from sigmoidal curve fitting are shown. Dotted line, rela-
tive productivity expressed as ratio between the slope of product concentration and growth at every timepoint. (B) Inser-
tion of the npt promotor sequence upstream of imd2 via a single-crossover homologous recombination approach. (C)
Relative roduction yields from cultivations of the S. aurantica Sg a15 wildtype (WT) and mutants Sga15HAL- (hal-), 
Sga15HutU- (hutU-), Sga15-stpk (stpk-), Sga15-sig54 (sig54-) and Sga15-npt (npt). White bars, without feeding; light 
grey bars, with feeding of histidine; dark grey bars, with feeding of urocanic acid. All values represent the mean of three
independent cultivations, normalized to the average wildtype production level which was set as "1". Error bars were cal-
culated from standard deviations (triplicate experiments). 
  4. Imidacin structure and biosynthesis 
The relative concentrations of compounds c319 and 
c347 were determined via LC-MS measurements 
(see methods) at various timepoints during growth 
of S. aurantiaca Sg a15 in liquid medium, in order 
to shed light on the correlation between their forma-
tion and growth of Sg a15. The results of this pro-
duction kinetics experiment are shown in Fig. 7A: 
Maximum productivity was observed at the onset of 
the exponential growth phase (ca. 30 h after inocula-
tion), and compound concentration did not increase 
further when the Sg a15 culture approached the sta-
tionary phase (at ~80 h and later). Thus, production 
of the urocanate metabolites seems to be modulated 
by a regulatory mechanism, which could possibly 
involve transcriptional control via a putative promo-
tor region upstream of the imd1–imd5 operon. 
Therefore, the mutant Sga15-npt was constructed, in 
which this operon was placed under the control of 
the constitutive npt promotor, utilizing a single-
crossover plasmid insertion approach (Fig. 7B). The 
production yields of compounds c319 and c347 
from Sga15-npt were approximately 5-folds higher 
when compared to the wildtype level, and increased 
further upon feeding of urocanate (ca. 6.5-fold) or 
histidine (up to 9-fold) (Fig. 4G and Fig. 7C). 
Growth characteristics and general phenotypic traits 
of the mutant strain Sga15-npt were largely un-
changed in comparison with the wildtype. 
 
Structural features of the urocanate-derived me-
tabolites c319 and c347 
Compound isolation and purification was car-
ried out by extracting the supernatants from shaking 
flask cultivations of Sga15-npt with ethyl acetate, 
followed by size exclusion chromatography and suc-
cessive rounds of reversed-phase liquid chromatog-
raphy. The final yield from a total culture volume of 
10 L was in the range of 0.2–0.3 mg. Compounds 
c319 and c347 were subjected to multiple stages of 
high-resolution tandem-MS analysis using static 
nano-electrospray ionization (nanoESI) and colli-
sionally induced dissociation (CID) on a linear trap–
orbitrap mass spectrometer. The obtained spectra 
(supplemental Fig. S2) suggest the initial two-step 
elimination of a terminal carboxylic acid group and 
the subsequent loss of multiple neutral fragments, 
with cleavages of carbon-carbon bonds occurring 
along an alkyl chain. This type of fragmentation pat-
tern may be explained by a charge-remote fragmen-
tation mechanism,[29] when the positive charge is 
located at the terminal imidazole moiety. This inter-
pretation is supported by the mass shifts observed 
from incorporation of 13C6-urocanic acid (Fig. 5) and 
by the calculation of high-confidence molecular 
formulae for fragments containing the imidazole-
acryl unit (Fig. S3). The CID fragmentation analysis 
also provided evidence for a modification of the 
carbon chain near to the carboxy terminus that ac-
counts for one double bond equivalent. 
The proposed structure was refined by GC-MS 
analysis following derivatization of c319 and c347 
with MSTFA (Fig. 8). The EI mass spectra indicate 
the presence of alkyl chains in both derivatives 
which differ in length by two methylene units, as 
concluded from the mass shift of 28 Da for a num-
ber of signals (marked with asterisks in Fig. 8). A 
distance of 40 Da between distinct fragments 
(marked with arrowheads in Fig. 8), likely resulting 
from C2–C3 and C4–C5 bond cleavage, respec-
tively, indicates the presence of a -C3H4- moiety 
between these positions, which is reasonably ex-
plained by a cyclopropane functionality. Indeed, a 
similar fragmentation behaviour has been observed 
previously in EI mass spectra of compounds with a 
cyclopropane group embedded in a comparable 
chemical environment, e.g. hexylcyclopropyl-
pyrrolidinyl-octanone (Supplemental Figure S3). 
This structural detail was further substantiated by 
the analysis of 1H-NMR data for compound c347, 
showing the expected signals for protons located at 
the disubstituted cyclopropane ring (supplemental 
Table S1). The NMR analysis also confirmed the 
presence of the imidazole acryl moiety and its con-
nection to the alkyl chain. The structure of the satu-
rated chain itself could not be determined in NMR 
experiments due to intense signal overlaps. Thus, 
compounds c319 and c347 were assigned the struc-
tures shown in Figure 9A based on the combined 
results of mass spectral- and NMR analysis and 
were named imidacins A1 and A2. These molecules 
may be regarded as formal analogs of fatty acids, 
featuring an urocanate starter unit and a cyclopro-
pane group located in the unusual 3-position. 
 
Incorporation of (methyl-d3)-L-methionine 
A variety of microorganisms, including E. coli 
and M. tuberculosis, are known to produce mem-
brane lipids that contain cyclopropyl fatty acids,[30] 
and it has been demonstrated that cyclopropane ring 
formation is accomplished through the action of 
cyclopropane synthases.[31,32] These SAM-dependent 
enzymes catalyze the methylenation (‘cyclopropana-
tion’) of unsaturated fatty acid precursors via addi-
tion of a methionine-derived methyl group to the 
double bond, followed by rapid proton loss (Fig. 
9B).[33] To probe the biosynthetic origin of the me-
thylene group in the cyclopropane moiety of com-
pounds c319 and c347, a culture of strain Sga15-npt 
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was supplemented with (methyl-d3)-L-methionine. 
The subsequent HPLC-MS analysis showed unam-
biguously that two deuterium labels were incorpo-
rated into the urocanate metabolites with high abun-
dance (Fig. 10A). Thus, the C3’ methylene unit is 
most likely derived from methionine, and a SAM-
dependent cyclopropane synthase is probably re-
sponsible for ring formation. The logical substrate 
for such an enzyme would be a 3-unsaturated pre-
cursor of the urocanate metabolites (Fig. 9B), and 
high-resolution LC-MS analysis revealed indeed the 
presence of a compound with matching elemental 
composition, plausible retention time and fragmen-
tation pattern in extracts from Sg a15 (supplemental 
Fig. S4). Moreover, a signal corresponding to a pu-
tative precursor with a completely saturated alkyl 
chain was also detected, albeit with very low abun-
dance. Taken together, these findings suggest that 
the late steps in the biosynthesis of compounds c319 
and c347 include the introduction of a double bond 
in the 3-position of a fatty acid-like precursor and 
subsequent SAM-dependent cyclopropanation (Fig. 
9B). Interestingly, imd4 encodes a protein with a 
conserved SAM binding site (Table 1 and supple-
mental Figure S5). 
Figure 8. GC-MS analysis of compounds c319 (imidacin A1) (A) and c347 (imidacin A2) (B) following derivatization with 
MSTFA, and structural assignment of fragments. Signals marked with an asterisk experience a mass shift of 28 Da,
when comparing both spectra. Black arrowheads highlight fragmentation flanking the cyclopropyl moiety. 
 
Discussion 
In this article, the discovery of two novel secon-
dary metabolites from S. aurantiaca Sg a15 is de-
scribed and a biosynthetic route for their formation 
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is proposed which depends on the supply of uro-
canic acid as a starter unit by histidine ammonium-
lyase. Related enzymes of the ammonium-lyase 
family that use phenylalanine or tyrosine as sub-
strates occur rarely in bacteria, but have been re-
ported previously to  provide  precursors  for  secon-
dary metabolite biosynthetic pathways.[20,22,34] HAL, 
in contrast, is found in many prokaryotes, but has 
been investigated exclusively in the context of cata-
bolic histidine utilization to date (Fig. 2). Notably, 
this study for the first time assigns a different role to 
HAL – specifically, to provide the urocanate build-
ing block for imidacin biosynthesis by S. auran-
tiaca. Both, the genomic localization of the gene 
encoding HALSa and its signficantly different kinetic 
parameters in comparison with other biochemically 
characterized HAL enzymes,[19] might be interpreted 
as evolutionary adaption to this unusual function: 
Placement of the HALSa-coding gene outside of a 
histidine utilization operon permits the independent 
regulation of its expression, while the low KM value 
determined in-vitro for HALSa enables it to retain 
catalytic efficiency even at low physiological his-
tidine concentrations. Moreover, high turnover 
numbers as achieved for example by HAL from P. 
putida are not required to effectively furnish the 
imidacin biosynthetic pathway with an urocanate 
precursor. Any other physiological significance of 
HAL-mediated histidine degradation for the primary 
metabolism of S. aurantiaca is at present unclear. 
The non-essentiality of HAL may enable the identi-
fication of further urocanate-dependent metabolites 
from other strains by comparing their metabolite 
profiles to those of HAL-inactivated mutants. 
To the best of our knowledge, the imidacins are 
the first natural products known to incorporate an 
urocanic acid moiety. The recruitment of carboxylic 
acids from bacterial primary metabolism for their 
use as starter units in secondary metabolite biosyn-
thesis has been demonstrated for a number of path-
ways to proceed via the activation as acyl-
adenylates by AMP-ligases, or as CoA-esters by 
CoA-ligase enzymes, respectively.[35] The activated 
building blocks are subsequently transferred onto 
the 4’-phosphopantheteine group of dedicated car-
rier proteins, where they are bound as thioesters. 
Alternatively, they can undergo further chemical 
transformations before being loaded onto the bio-
synthetic assembly line. Well-established examples 
(among many others) for these modes of starter unit 
sequestration include the activation of 2,3-
dihydroxybenzoic acid by the adenylating enzymes 
during enterobactin biosynthesis (EntE) and 
myxochelin (MxcE) biosynthesis, respectively.[13,36] 
Another example is the formation of cinnamoyl-
CoA by the CoA-ligase EncH as an early step in 
enterocin bioynthesis.[34] Two candidate proteins, 
which could accomplish the activation of urocanate 
in analogous ways, were found in the genomic re-
gion identified by transposon mutagenesis as essen-
tial for imidacin biosythesis: the first domain en-
coded by imd1 shows similarity to EntE and MxcE, 
while one domain encoded by orf7 exhibits similar-
ity to CoA-ligases (Fig. 6). Targeted gene inactiva-
tion experiments revealed unambigously that the 
protein encoded by orf7 has no function in imidacin 
biosynthesis; in contrast, disruption of imd1 abol-
ished imidacin production. Thus, the adenylation 
domain Imd1-A is likely to be responsible for the 
activation of urocanic acid as urocanyl-AMP, 
probably followed by transfer onto the integral car-
rier protein domain Imd1-ACP (Fig. 9B). Feeding of 
13C6-urocanate revealed that the complete urocanate 
backbone is preserved in the imidacin structure, ar-
guing against the activation of a hypothetical trun-
cated derivative of urocanate by Imd1-A. Further-
more, this finding rules out the possibility that 
activated urocanate undergoes further modifications 
associated with loss of carbons, for example via a -
oxidative route as it has been reported for cinnamate 
in the course of enterocin biosynthesis.[34] 
An enoylreductase domain, Imd1-ER, is located 
in between the A domain and the ACP encoded by 
imd1. A similar domain arrangement is found in the 
loading module of the rapamycin biosynthetic gene 
cluster, where the enyolreductase has been shown to 
reduce the double bond of the dihydroxycyclohex-
ene carboxylic acid starter unit.[37] However, the 
double bonds in the imidazole-acryl moiety of uro-
canate are apparently transferred into the final struc-
ture of the imidacins. Thus, Imd1-ER does pre-
sumably not process the urocanate-ACP 
intermediate, even though this domain should be 
regarded as functional as judged by the presence of 
intact signature motifs in its amino acid sequence. 
Following selection and loading of the urocanic 
acid starter unit, we reason that the linear scaffold of 
the imidacins derives from multiple rounds of chain 
elongation according to PKS biosynthetic logic. The 
existence of two imidacin derivatives which differ in 
chain length by one -C2H4- unit suggests that their 
biosynthesis involves an iterative mechanism for 
carbon chain elongation (Fig. 9B). A suitable candi-
date module is encoded by imd2, which has the full 
complement of KS, AT, DH, ER, KR and ACP do-
mains to catalyze one step of chain extension includ-
ing ketoreduction, dehydration and enoylreduction 
of the ACP-bound intermediate. The integral Imd2-
AT domain exhibits the required substrate specific-
ity  for  malonyl-CoA,  according  to  the conserved 
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Figure 9. (A) Structures of the two novel metabolites imidacin A1 and A2. (B) The proposed biosynthetic route for the 
formation of imidacins by S. aurantiaca Sg a15, starting with the conversion of L-histidine to urocanate. 
  4. Imidacin structure and biosynthesis 
HAFH motif in its sequence.[38] Unusual but not un-
precedented iterative use of module Imd2 would 
then result in formation of the linear, completely 
reduced carbon backbone of imidacins A1 and A2 
after six and seven rounds of catalysis, respectively 
(Fig. 9B). The iterative use of modules in bacterial 
type I PKS has been reported previously from a 
growing number of myxobacterial and streptomy-
cete megasynthetases.[18,39] For example, the polyene 
side chain of myxochromides is generated by only 
one PKS module (including a non-functional ER 
domain) which is capable of producing unsaturated 
polyketide chains of variable length.[7] Programmed 
iteration of a single module is believed to be in-
volved in stigmatellin biosynthesis and was recently 
shown to lead to variable chain lengths during 
bioynthesis of the DKxanthenes.[11,40] Similarly, the 
natural products aureothin, avilamycin and borel-
lidin from streptomycetes have been shown to origi-
nate, at least in part, from iterative type I PKS bio-
chemistry.[41-43] However, to the best of our 
knowledge none of the PKS biosynthesis pathways 
investigated to date delivers a fully reduced and un-
branched alkyl chain mimiking the outcome of fatty 
acid biosynthesis, by the repeated action of only one 
PKS module. The variable length of the PKS-
derived scaffold in imidacins A1 and A2 may be ex-
plained by a lack of stringent chain length control. 
This hypothesis will have to be addressed in further 
studies as the mechanisms underlying chain length 
control in iterative PKS systems still await clarifica-
tion. 
An additional module harboring PKS biosynthe-
sis-related domains (KS, AT, DH, ACP) is encoded 
by imd3 (Fig. 6). All domains seem to be functional, 
as judged by the presence of conserved sequence 
motifs, and Imd3-AT is predicted to exhibit the 
same substrate specificity for malonyl-CoA as 
Imd2-AT. However, the absence of a ketoreductase 
domain renders the integral DH domain useless and 
thus argues against a role of this module in imidacin 
biosynthesis, since all incorporated building blocks 
are fully reduced in the final imidacin structure. Dis-
ruption of imd3 by transposon insertion abolished 
imidacin production in mutant Sga15-29F10 (Fig. 
6), but this finding might be explained by a polar 
effect on the downstream genes (see below). 
The products of PKS-type biosynthetic path-
ways are usually released from the assembly line by 
a dedicated thioesterase (TE) domain located at the 
C-terminal end of the last module in the respective 
pathway. A typical TE domain is not encoded within 
the region that was sequenced here, but an enzyme 
with convincing similarity to proteins of the /-
hydrolase family, including representatives that ex-
hibit esterase activity, is encoded by the open read-
ing frame imd5, located between imd3 and imd1 
(Fig. 6). Targeted inactivation of this gene led to a 
mutant deficient in imidacin production. This result 
is unlikely to arise from polar effects, since imd1 
(which is preceeded by a non-coding region, suffi-
cient in length to contain a promoter) is probably 
transcribed independently from imd5, and the hypo-
thetical involvement of orf3, encoding a short ‘leu-
cine-rich repeat’ protein, in imidacin biosynthesis is 
considered highly implausible. Thus, we propose 
that imd5 encodes an enzyme that catalyzes hydro-
lytic release of the fully chain-elongated and com-
pletely saturated imidacin precursor from Imd2 as 
the free acid (Fig. 9B). Notably, two members of the 
/-hydrolase enzyme family, MonCII and NanCII, 
have recently been revealed as novel chain-
terminating thioesterases in monensin and 
nanchangmycin biosynthesis, respectively.[44,45] The 
amino acid sequences of these proteins displayed 
low overall similarity to known thioesterases from a 
variety of PKS biosynthetic pathways, but share 
with them the typical /-hydrolase fold and an es-
sential serine residue at the active site.[44] The same 
holds true for the putative /-hydrolase Imd5 (see 
also supporting information, Figure S5) and thus 
suggests Imd5 to function as a thioesterase. 
The final imidacin structure exhibits a cyclopro-
pane moiety likely resulting from the methylenation 
of a double-bond by an SAM-dependent cyclopro-
pane synthase, as concluded from the incorporation 
of two deuterium labels after feeding of (methyl-
d3)-L-methionine (Fig. 10). High-resolution LC-MS 
analysis of cell extracts provided evidence for the 
presence of both a fully saturated and a mono-
unsaturated imidacin precursor, named imidacin C 
and B, respectively (supplemental Figure S4). We 
therefore propose that desaturation and cyclopro-
panation take place as post-PKS modifications with 
high efficiency (Fig. 9B). In the absence of a suit-
able candidate gene for a desaturase that could de-
liver the 3-mono-unsaturated imidacin precursor 
for subsequent cyclopropanation, we assume that 
this function is carried out by an enzyme encoded 
elsewere in the Sg a15 genome. Intriguingly, the 
cloning and biochemical characterization of the first 
desaturase with 3-regioselectivity has been reported 
very recently from a fungal source.[46] We cannot 
exclude, however, the possibility that the double 
bond is incorporated during PKS assembly. Never-
theless, this seems unlikely due to the unusual dou-
ble bond geometry which is only found rarely in 
PKS products[17]. It may be speculated about the un-
orthodox formation of this double bond by an enoyl-
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reductase domain catalyzing the inverse reaction. 
The Imd1-ER domain (which lacks a role in the re-
spective chain extension cycle) could theoretically 
introduce the 3 double bond in this way. However, 
this would also require that Imd1-ER processes a 
chemical moiety in the imidacin structure which is 
located distantly to the part of the molecule assem-
bled by Imd1. 
Enzymes capable of introducing a cyclopropane 
ring into unsaturated fatty acid scaffolds via the ad-
dition of an SAM-derived methylene group have 
been described in E. coli and M. tuberculosis. How-
ever, these enzymes do not exhibit the regioselectiv-
ity that would be required for imidacin cyclopro-
panation: The E. coli cyclopropane synthase usually 
processes -unsaturated fatty acids contained in 
cell wall phospholipids, while two distinct cyclo-
propane synthase enzymes in M. tuberculosis trans-
form distantly positioned double bonds into cyclo-
propane moieties in the long-chain mycolic 
acids.[30,47] A candidate enzyme for imidacin cyclo-
propanation is encoded by imd4, as suggested by the 
presence of a conserved SAM-binding motif in the 
deduced amino acid sequence (supplemental Figure 
S5).[48] Although Imd4 is more similar to HemN-like 
proteins which belong to the 'radical SAM' super-
family rather than to known cyclopropane syn-
thases,[49] it is most likely not a functional HemN-
analog because a signature CxxxCxxC motif found 
to date in all known 'radical SAM' enzymes is absent 
(Figure S5).[48] Thus, Imd4 may instead constitute a 
novel type of cyclopropane synthase involved in the 
formation of imidacins A. However, we cannot ex-
clude at present that the relevant enzyme is encoded 
outside the imidacin biosynthetic gene cluster, just 
as proposed above for the missing desaturase. 
Figure 10. Mass spectra of imidacin A1 (compound c319, left) and imidacin A2 (compound c347, right) obtained from a 
culture of Sga15-npt (A) and a feeding experiment where the same strain was supplemented with (methyl-d3)-L-
methionine (B), revealing the incorporation of two deuterium labels into the cyclopropane ring moiety. 
Genes involved in regulation of secondary me-
tabolite production are sometimes encoded within or 
in the immediate vicinity of biosynthetic gene clus-
ters. Two genes with conceiveable regulatory roles 
were identified upstream of the imd operon: orf1 
encodes a putative serine/threonine protein kinase 
(STPK) and orf2 encodes a 54 transcriptional acti-
vator (Fig. 6). However, targeted inactivation of orf1 
and orf2 did not influence the production of imi-
dacins by the respective mutant strains (Figure 7C), 
and we conclude therefore that the STPK and the 54 
transcriptional activator are not involved in the regu-
lation of imidacin biosynthesis. 
In summary, the genes that direct imidacin for-
mation in Sg a15 are split across at least two, more 
likely three distant loci in the genome, and the or-
ganization of genes encoded within the imd operon 
is not colinear with the proposed biosynthesis. Fur-
thermore, not all theoretically required genes could 
yet be identified, but on the other hand some of the 
encoded functions are apparently not required. It 
seems plausible that the imd operon was placed in 
the genome of strain Sg a15 as part of a sequence 
transposition event – this idea is supported by the 
unusually low GC content in the preceeding inter-
genic gap and the sequence remains of a putative 
transposase. The seemingly redundant or cryptic 
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genes (e.g. imd3, orf3) could thus represent evolu-
tionary artifacts. 
The assignment of some biological role for imi-
dacins in the producing host Sg a15 must at present 
remain largely speculative. Cyclopropyl fatty acids, 
representing the closest structural analogs of imi-
dacins, occur frequently as constituents of cell wall 
lipids in a variety of bacteria, where they are thought 
to modulate membrane fluidity in response to envi-
ronmental influences.[30] Cyclopropyl-modified my-
colic acids have also been implicated in pathogenic-
ity of M. tuberculosis.[47] The imidacins could in 
principle be part of the S. aurantiaca cell envelope; 
however, tentative attempts to obtain free imidacins 
from crude cell lysates by saponification of hypo-
thetical esters were unsuccessful (data not shown), 
suggesting that the imidacins are not major constitu-
ents of lipids in S. aurantiaca. In light of the ex-
traordinarily low, growth phase-dependent produc-
tion of imidacins, and taking into account the 
generally complex lifestyle of myxobacteria, an as 
yet unrecognized regulatory role or their use as 
strain-specific signal molecules should also be con-
sidered. 
Besides the unclear biological significance of 
imidacin production for S. aurantiaca Sg a15, the 
question needs to be addressed in future studies 
whether genes without a predicted function for imi-
dacin biosynthesis are actually dispensable. More-
over, the proposed roles of certain candidate genes 
and domains encoded within modules require con-
firmation by targeted inactivation and mutational 
analysis. Unfortunately, genetic manipulation of S. 
aurantiaca Sg a15 is limited by the availability of 
reliable selection markers and, despite serious ef-
forts to establish better genetic systems, the lack of a 
method for introducing markerless mutations (Julia 
Hovermann and R.M., unpublished results). Thus, 
further investigations would clearly benefit from 
heterologous expression of the complete imidacin 
pathway, for which the stage has been set by cloning 
of relevant genes in this study. Experiments aimed 
at the identification of the missing desaturase gene 
and the biochemical characterization of the unusual 
cyclopropane synthase and hydrolase enzymes are 
currently under way. 
 
Significance 
The impressive structural diversity of microbial 
secondary metabolites stems from the virtually 
unlimited combinations of biosynthetic building 
blocks, the various ways of assembly into more 
complex biosynthetic intermediates, and the enzy-
matic transformations that decorate a core structure 
with additional features to finally result in each 
natural product's intriguing characteristics. The 
structure of the novel metabolites reported here, and 
the biosynthetic machinery that achieves their for-
mation, are remarkable in several respects. First, an 
unprecedented urocanic acid starter unit is provided 
by a histidine ammonium-lyase. Urocanate is subse-
quently activated and elongated by an iterative PKS 
module to yield a completely reduced linear back-
bone. The resulting fatty acid-like scaffold is then 
further modified with a rare cyclopropane moiety, 
which presumably results from the successive action 
of a desaturase and methylenation by a cyclopro-
pane synthase. The corresponding enzymes are 
commonly associated with fatty acid metabolism. In 
imidacin biosynthesis they seem to exhibit excep-
tional substrate specificity and regioselectivity not 
previously observed in bacteria. 
In conclusion, a variety of enzymatic activities 
from unrelated biosynthetic pathways cooperate in 
S. aurantiaca Sg a15 to produce the unique imidacin 
structure. Genes encoding the required functions are 
distributed over multiple locations in the Sg a15 ge-
nome, rendering it highly unlikely that the biosyn-
thetic route, let alone its product, would be predict-
able by bioinformatic methods using whole-genome 
data. Therefore, the discovery of the imidacins high-
lights the value of combined molecular biological 
and metabolic profiling approaches to mining the 
myxobacterial natural product repository – exempli-
fied here by the identification of a novel compound 
class through comparison of metabolite profiles fol-
lowing inactivation of the general histidine utiliza-
tion pathway. The biosynthetic capabilities that form 
the basis of such unexpected secondary metabolite 
diversity, in particular those that accomplish the ac-
tivation of unusual monomeric building blocks or 
carry out rare chemical transformations, represent 
useful additions to the enzymatic ‘toolbox’ for the 
design and genetic engineering of biosynthetic 
pathways. 
 
 
Experimental procedures 
Chemicals, media, strains and fermentation condi-
tions – All chemicals were purchased from Sigma-
Aldrich unless indicated otherwise. E. coli strain DH10B 
was grown at 37 °C and strain BL21 was grown at 30 °C 
in Erlenmeyer flasks in liquid LB medium, supplemented 
with the following antibiotics whenever appropriate: am-
picillin, 100 µg/mL; kanamycin sulfate, 50 µg/mL. Stig-
matella aurantiaca Sg a15 and its decendants were grown 
in liquid tryptone medium (ref) at 30 °C and 200 rpm and 
maintained on TS agar plates,[1] containing kanamycin 
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when required for selection. The sequences of primers 
can be found in the supplemental material (Table S2). 
Recombinant production, purification and activity 
assay of HALSa – Heterologous expression of SaHAL was 
achieved as C-terminal fusion to glutathione S-transferase 
(GST). The primer pair HALSga15start and HAL-
Sga15stop was employed for the PCR-amplification of a 
1527 bp-fragment from genomic DNA of strain S. auran-
tiaca Sg a15 using Pfu polymerase (Promega), adding 
mutageneic BglII and SalI restriciton sites. The fragment 
was digested accordingly and ligated to the BamHI/SalI-
digested pGEX-6P-1 vector backbone (Invitrogen), using 
T4 DNA Ligase (MBI-Fermentas). Following transforma-
tion into E. coli DH10B, plasmid DNA was prepared us-
ing the GeneJet plasmid isolation kit (MBI-Fermentas) 
and the insert of the obtained plasmid pGEX-SaHAL was 
sequence-verified (MWG Eurofins). E. coli BL21, trans-
formed with the pGEX-SaHAL expression plasmid, was 
grown overnight in 2 mL LB medium with ampicillin, 
and was inoculated at a 1:100 dilution into 50 mL LB 
medium containing ampicillin. When growth reached an 
OD600 of 1.0, IPTG was added to a final concentration of 
0.2 mM, and cultivation was continued for 2.5 h at 30 °C. 
Cells were harvested by centrifugation, resuspended in 
PBS buffer and passed twice through a French pressure 
cell. The crude lysate was clarified by centrifugation and 
protein purification was carried out by affinity chroma-
tography using GST-Sepharose. The GST tag was 
cleaved with PreScission Protease at 4 °C according to 
the manufacturer’s recommendations and the purified 
protein was eluted in buffer containing 50 mM Tris (pH 
7.0), 150 mM NaCl, 1 mM EDTA, and 1 mM dithiothrei-
tol. Enzyme activity was assayed using 1–10 µg purified 
protein in 0.1 M Tris buffer (pH 8.8) at 30 °C, with sub-
strate concentrations ranging from 50 µM–4 mM L-
histidine, or up to 5 mM phenylalanine or 2 mM tyrosine. 
Protein concentrations were determined using the colori-
metric assay described by Bradford with chemicals sup-
plied by BioRad.[50] 
Cloning of an hutU-homologous fragment from S. 
aurantiaca Sg a15 – The degenerate primer pair 
HutU_QMTA, 5’-GCCTGATGATGTACGGCCARAT 
GACNGC-3’ and HutU_PGFV (5’-CGGATGTACGCC 
GGCACRAANCCNGG-3’ (degenerate regions are un-
derlined) was designed using the CODEHOP ap-
proach,[51] and used for the PCR-amplification of a 682-
bp fragment from genomic DNA of S. aurantiaca Sg a15. 
The fragment was cloned into the pCR2.1Topo vector 
(Invitrogen) to yield the plasmid pTOPO-Sga15hutU, the 
insert sequence of which was determined by sequencing. 
Targeted gene inactivation in S. aurantiaca Sg a15 – 
In general, an internal fragment (500–800 bp in size) of 
the gene to be inactivated was PCR-amplified from ge-
nomic DNA using Taq polymerase and sequence-specific 
primers (listed in supplemental Table S2), and cloned into 
the pCR2.1Topo vector. The resulting inactivation plas-
mid was used for electroporation of S. aurantiaca Sg a15 
as previously described.[27] Viable colonies were obtained 
on TS agar supplemented with kanamycin, and chromo-
somal DNA was pepared from liquid cultures using the 
Puregene Kit (Gentra). Integration of the plasmid into the 
correct genomic locus was routinely verified by PCR, 
using control primers (Table S2) which are located out-
side the amplified region, in combination with vector-
specific primers pTOPOin and pTOPOout. 
HPLC-MS analysis of S. aurantiaca Sg a15 metabo-
lite profiles – Typically, a 50 mL shaking flask culture of 
S. aurantiaca Sg a15 was grown for 72–84 hours, clari-
fied by centrifugation, and the supernatant was extracted 
with excess ethyl acetate. Following evaporation of the 
solvent until complete dryness, the solid residue was re-
dissolved in 1 mL of methanol. A 5 µL aliquot was used 
for injection into an Agilent 1100 series HPLC-DAD 
system coupled to a Bruker HCTplus ESI-iontrap MS 
device. Chromatographic separation was performed on a 
Luna RP-C18 column (100 x 2 mm, 2.5 µm particle size; 
Phenomenex, Germany) equipped with a 4 x 2 mm C18 
guard cartridge. The mobile phase system consisted of 
water (A) and acetonitrile (B), each containing 0.1 % 
formic acid. Linear gradients from 5 %B to 95 %B were 
routinely employed at a flow rate of 0.4 mL/min, and the 
column temperature was held at 32 °C. MS analysis was 
carried out in positive ionization mode. A tandem-MS 
method was used for quantitative measurements, which 
records the intensities of [M-H2O+H]+ fragments derived 
from the parent ions with [M+H]+ = 319 m/z and [M+H]+ 
= 347 m/z. 
HPLC-MS based screening of a library of Sg a15 
mutants and plasmid recovery – The construction of a 
library of S. aurantiaca mutants harbouring random inser-
tional gene inactivations was reported previously.[16] 
Briefly, S. aurantiaca Sg a15 was transformed with the 
mariner-based transposon plasmid pMycoMar,[52] and 
viable clones were subsequently selected on TS agar con-
taining kanamycin and transferred to 150 µL tryptone 
medium (with kanamycin added) in 96-well plates. After 
growth for 5 days at 30 °C and 700 rpm on a wellplate 
incubator (Infors), 50 µL aliquots from each well were 
added to 100 µL methanol, the suspension was clarified 
by centrifugation and 15 µL aliquots from the supernatant 
were subjected to HPLC-MS analysis. Separation was 
carried out on a RP-C18 column (Nucleodur, 125 x 2 
mm, 3 µm particle size, Macherey & Nagel) equipped 
with a precolumn (8 x 3 mm, 5 µm partile size), with in-
strumentation and a mobile phase system essentially as 
described above. Detection of the target compounds with 
high sensitivity and selectivity was achieved by operating 
the ion-trap in manual tandem-MS mode and recording 
the intensity of [M-H2O+H]+ fragment ions derived from 
the precursors with [M+H]+ = 319 m/z and [M+H]+ = 347 
m/z, respectively. For plasmid recovery from mutant 
Sga15-29F10, chromosomal DNA was digested with 
SmaI, re-ligated using T4 DNA ligase and used for the 
transformation of E. coli DH5pir. The obtained plas-
mid p29F10 was used to determine the cloned sequence 
flanking the transposable element, using primers K388 
and K390[52]. Treatment of p29F10 with SmaI followed 
by ligation to the SmaI-digestested pBluescriptSK vector 
 
88  Manuscript 
  4. Imidacin structure and biosynthesis 
backbone gave plasmid p29F10Sma, which was used for 
sequencing into the region in between the former chro-
mosomally-encoded SmaI restriction sites, utilizing stan-
dard M13 primers. 
PCR-screening of a Sg a15 cosmid library – The 
construction of a cosmid library in E.coli SURE using the 
Supercos Vector (Stratagene), containing 35-48 kbp 
fragments of the Sg a15 chromosome, was described pre-
viously.[27] Pools consisting of 96 cosmids were initially 
employed as template for the PCR-amplication of frag-
ments from the genes imd2 and imd5 (Fig. 6), using prim-
ers listed in supplemental Table S2. Subsequently, addi-
tional rounds of PCR using pools of 32 cosmids and 
finally the single cosmids as templates were carried out to 
identify the overlapping cosmids cos13F7 and cos11D1. 
These cosmids were introduced into E.coli DH10B by 
electroporation, and cosmid DNA prepared with the 
GeneJet Kit (MBI Fermentas) was used for sequencing 
(MWG Eurofins). 
Insertion of an upstream npt promotor adjacent to 
orf1 – The npt (neomycin phosphotransferase) promotor 
sequence was PCR-amplified from the plasmid 
pCR2.1Topo (Invitrogen) using Phusion polymerase 
(Finnzymes) and primers Mch71 and Mch72,[53] adding a 
modified RBS sequence (Silke C. Wenzel, unpublished). 
The amplified fragment 157 bp in size was gel-purified 
and used in a subsequent overlap-extension PCR step, in 
combination with primers Mch71 and Sga15con4b and a 
1073-bp fragment previously amplified from cosmid 
cos13F7 using the primer pair Sga15act3neu2 and 
Sga15con4b (supplemental Table S2). Following the ad-
dition of single A-overhangs to the resulting PCR product 
by Taq polymerase, the gel-purified fragment 1209 bp in 
size was cloned into the pCR2.1Topo vector to give 
plasmid pTOPO-Sga15act. The correct fusion of the npt 
sequence to the orf1-homologous region was verified by 
sequencing, and the plasmid was used for the transforma-
tion of S. aurantiaca Sg a15, yielding strain Sga15-npt. 
Preparation of samples for GC-MS analysis – Ex-
tracts were separated by HPLC as described above, and 
fractions corresponding to the retention times of com-
pounds with 319 m/z and 347 m/z were collected. Sol-
vents were removed from the samples by evaporation to 
complete dryness, and the residue was dissolved in di-
methylformamide or pyridine. An equal volume of 
MSTFA was added and the reaction was allowed to pro-
ceed for 1 h at 60 °C prior to injection into the 6890N 
GC-MS analyzer with MSD (Agilent Technologies, Ger-
many). 
Direct-infusion high-resolution ESI-MS measure-
ments – Samples were seperated on a RP-C18 column (50 
x 2 mm, BEH, 1.7 µm particle size; Waters, Germany) 
using an Accela ultra-high performance liquid chroma-
tography system (Thermo-Fisher), and fractions were 
collected in 96-well plates (Abgene, Germany) with the 
Triversa NanoMate system (Advion, UK). The fractions 
were dried under nitrogen and a mixture of 50 % aqueous 
methanol, containing 0.1 % formic acid, was added. 
Static electrospray of sample aliquots was achieved using 
the automated chip-based nanoESI capability of the 
NanoMate device with parameters as follows: spray volt-
age, 1.7 kV; back pressure, 30 psi. Detection was per-
formed on the LTQ-Orbitrap mass spectrometer (Thermo-
Fisher) which was set to a resolution of 30,000 (FWHM 
at 400 m/z) with internal lock-mass calibration. Multiple 
stage tandem-MS studies were conducted in the linear 
trap using relative normalized CID energies in the range 
of 20–35%. 
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Supplemental Figure S5 
 
A) Protein sequence of Imd4. Residues on grey background: glycine-rich motif putatively involved 
in SAM binding; boxed residues: hypothetical artifacts of “radical SAM-like” cysteine motif. 
 
MKPSVSRSARSSVEAARDFIERNLNVRQVNKVLHAFPSPRMWQETDIPVRERLEERKAAQESRE
LALYVAVPYCIRTDPDRCGYCLFPVEVYTGNNDLDTYFTYLRREGELYRGLFEKDRVVNIYFG
GGTSNLYRADKYPQLMDLVREHFTLPTDSSITLEGIPQLFTREKLQKIKESGMNRVSMGVQQMN
DELNALSGRKQTVKHTLQSIEWCQELGLPCNVDLIFGWPRQTVATMMKDLELLVSTGIHHITHY
ELNVGGPTDFALNRRHELPSVAENLEMYRVSRDFLKSRGYVQLTPYDWEKIDAPEQSLYEECDR
DFRAMDIFGWGYAGVSQFAGVGGRSAWTYRQHTSIKDYYKAIDEGRIPLEHGFTHQEVDYRLSQ
LFRNLQGLEVDLDAYQRAFGVELLDEYAGAWQALAERGFVEIEGRKLRLVGDGVFYTPMIQTLL
SRERIAELSSSLRASVRPAASVGV 
 
 
B) Protein sequence alignment of Imd5 with MonCII and NanE. The asterisk above the se-
quences denotes the putative active-site serine residue. 
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Supplemental Table S1 
 
1H-NMR data for imidacin A2 (c347). 
 
A) 
1H NMR (MeOD, 400 MHz):  = 0.65 – 0.70 (m, 1H, CH2), 0.85 – 0.91 (m, 1H, CH2), 1.04 – 1.09 
(m, 1H, CH), 1.13 (dd, 1H, 3JH,H = 2.7, 6.2 Hz, CH), 1.25 – 1.42 (m, 18H, 9 x CH2), 1.46 (quin, 2H, 
3JH,H = 6.8 Hz, CH2), 2.17 (q, 2H, 3JH,H = 7.1 Hz, CH2), 6.15 (dt, 1H, 3JH,H = 6.9, 15.9 Hz, CH), 6.27 
(d, 1H, 3JH,H = 16.0 Hz, CH), 6.94 (s, 1H, CH), 7.66 (s, 1H, CH), 8.45 (s, 1H, NH) ppm. 
 
B) 
H,H-COSY 
Nr. ppm Multiplicity Integral 3JH,H / Hz H,H-COSYa Interpretation 
1 0.65 – 0.70 m 1  3, 5 Cyclopropyl-CH2b 
2 0.85 – 0.91 m 1  5 Cyclopropyl-CH2b 
3 1.04 – 1.09 m 1  1, 5 Cyclopropyl-CH 
4 1.13 dd 1 2.7, 6.2 5 Cyclopropyl-CH 
5 1.25 – 1.42 m 18  1 – 4, 6  9 x CH2, Alkyl chain 
6 1.46 quin 2 6.8 5, 7 CH2-CH2CH=CHc 
7 2.17 q 2 7.1 6, 8 CH2-CH2-CH=CHc 
8 6.15 dt 1 6.9, 15.9 7, 9 CH2CH2-CH=CHc 
9 6.27 d 1 16.0 8 CH2CH2CH=CHc 
10 6.94 s 1   Imidazole-CH 
11 7.66 s 1   Imidazole-CH 
12 8.45 s 1   Imidazole-NH 
 
a Number of signal according to column 1 in this table, for which a crosspeak can be seen in the H,H-COSY 
spectrum. 
b 1H-NMR signal represents one of the diastereotopic protons in the cyclopropyl ring CH2-moiety.  
c protons assigned to this 1H-NMR-signal are printed in italics. 
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Supplemental Table S2 
 
 
HALSga15start  5’-ATGTCCCAGATCTCCCCGCTTGAAC-3’ 
HALSga15stop  5’-CTACTGTCGTCGACCGCGTCGCGGTG-3’ 
HALSga15fwd1  5’-GTGCTGGCCAAGGGCTATTCG-3’ 
HALSga15rev1  5’-GCAATCATGAAGCCCGAGTTG-3’ 
Sga15con1   5’-GGTGCTGCTCTTGCTGCGTTG-3’ 
Sga15con2   5’-AGCTCCCGGTCCTTTTCCATG-3’ 
Sga15con3   5’-CCGAGGGCTGCGGCATGTTGGTC-3’ 
Sga15con4   5’-AGCGCCGCGCGGTGCTCAAAGTG-3’ 
Sga15inakt2f  5’-CACGGTGGCCTGTGGCAGCGCATGG-3’ 
Sga15inakt2r  5’-CTGCGGCCGCGGTGAAGCTGAGGTC-3’ 
Sga15inakt3f  5’-CTCGGCAGCGGGCAGGCAGCAAGAC-3’ 
Sga15inakt3r  5’-GGGCTTCGTGGGTGCCTCGTGGATG-3’ 
pTOPOin   5’-CCTCTAGATGCATGCTCGAGC-3’ 
pTOPOout   5’-TTGGTACCGAGCTCGGATCC-3’ 
Sga15con5   5’-GTAGCGGTTCTCCATGGTCTGGAAG-3’ 
Sga15con6   5’-TCGGTTGGAGTCTGAGGATCCAC-3’ 
cos13F7_19F2rev  5’-GTGATGTCCTGCAGTCGCTTG-3’ 
cos13F7_18F  5’-CCCGAACTTCGCCTATGAG-3’ 
cos11D1_7Rrev  5’- TCGCGCACCTGGGGATGATC-3’ 
cos13F7_6R  5’- GTGGCCCACCAATACGAAG-3’ 
Sga15act3neu2  5’-GATAAGGAGGTACAGATTATGCGAAGATCGACTG-3’ 
Sga15con4b   5’-CCCACTCGCAGGAGTTGTG-3’ 
HutU_QMTA  5’-GCCTGATGATGTACGGCCARATGACNGC-3’ 
HutU_PGFV   5’- CGGATGTACGCCGGCACRAANCCNGG-3’ 
K388   5’-TGGGAATCATTTGAAGGTTGG-3’ 
K390   5’-GGGTATCGCTCTTGAAGGGAAC-3’ 
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1.  General scope of this work 
This thesis deals with aspects of secondary metabolite biosynthesis in myxobacteria, with 
particular focus on the biosynthetic origin of unusual building blocks incorporated into myxo-
bacterial natural products. Detailed molecular and biochemical studies were carried out, in order 
to delineate the involved metabolic pathways and to explore the underlying enzymology. Ge-
netic engineering was used to establish structure-activity relationships for one selected enzyme 
from Chondromyces crocatus, demonstrating the feasibility to tailor its catalytic properties for 
potential biotechnological applications. Moreover, targeted gene inactivation and feeding studies 
led to the discovery and structure elucidation of a unique class of secondary metabolites from 
Stigmatella aurantiaca. Investigating the biosynthetic route for the formation of these com-
pounds revealed a novel branching point from bacterial primary metabolism. Besides the seques-
tration of an unprecedented starter unit, this new pathway was also shown to include several in-
triguing enzymatic reactions. Both, the use of unusual building blocks and uncommon 
enzymatic transformations, contribute to the generally impressive structural diversity of myxo-
bacterial secondary metabolites. 
Furthermore, a mass spectrometric method was devised for the characterization of myxobac-
terial metabolite diversity. The metabolomics-based approach employed here, in combination 
with statistical evaluation, paves the way for an enhanced, comprehensive view of complex 
myxobacterial secondary metabolomes. The complexity of the species-wide secondary metabo-
lite inventory of Myxococcus xanthus could be shown to match the previously established ge-
netic capacity of this species for natural product biosynthesis. The implementation of advanced 
mass spectrometric techniques within an analytical framework for the mining of microbial me-
tabolite profiles is described. These methods should facilitate the future discovery of novel natu-
ral products not only from myxobacteria. 
 
C. Discussion 
2.  Biosynthesis of -tyrosine by tyrosine 2,3-aminomutase enzymes and its in-
corporation into natural products 
Biosynthesis of (R)--tyrosine and its incorporation into the chondramides. 
The chondramides produced by C. crocatus exhibit striking structural similarity to the jas-
pamides (jasplakinolides), a family of depsipeptides derived from the marine sponge Jaspis 
spledens (Figure C-1).[93] Based on the assumption that the corresponding biosynthetic pathways 
should be highly similar, it was suggested that the stereochemistry of the -tyrosine moiety in 
the chondramides should match the (R)-configuration found in the jaspamides.[44] This expecta-
tion was confirmed in this work. Very recently, the configurational assignment of all stereo-
centers in the chondramide structure was accomplished by NMR analysis, and thus the presence 
of a (R)--tyrosine moiety has been independently validated.[94,95] 
The biosynthesis of a (R)--Tyr building block and its mode of incorporation into a natural 
product have not been investigated previously, but the sequencing of the chondramide biosyn-
thetic gene cluster afforded an opportunity to probe the biosynthetic origin of this unusual -
amino acid.[44] It was hypothesized that (R)--Tyr could be produced directly from L-tyrosine by 
CmdF, an enzyme encoded in the cmd gene cluster showing significant homology to the tyrosine 
aminomutase SgcC4 producing (S)-ß-Tyr in the S. globisporus enediyne pathway. CmdF was 
shown by targeted gene inactivation to be essential for chondramide biosynthesis. Complemen-
tation of the cmdF- mutant could be achieved through feeding of (R)--Tyr, but not (S)--Tyr. 
Figure C-1.  Structures of chondramides 46 from the myxobacterium C. crocatus Cm c5 and jaspamide 47 from the 
marine sponge Jaspis spledens. Chondramide A, R1= -OCH3, R2 = H; chondramide B, R1 = -OCH3, R2 = Cl; chondra-
mide C, R1 = R2 = H; chondramide D, R1= H, R2 = Cl.  
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On the contrary, the tyrosine aminomutase SgcC4 (the only characterized TAM enzyme at the 
onset of this study) has been shown to produce preferentially (S)--Tyr in vitro, which is found 
in the enediyne product C-1027. This difference prompted further investigation of the catalytic 
properties of CmdF, and therefore heterologous expression was carried out. The biochemical 
characterization of recombinant CmdF revealed this enzyme as a novel member of the TAM 
family, converting L-tyrosine predominantly to (R)--Tyr. CmdF thus exhibits stereoselectivity 
consistent with its function to supply the (R)--Tyr building block for chondramide formation in 
C. crocatus. However, CmdF also produced significant amounts of the opposite enantiomer in 
vitro, but (S)--Tyr is not incorporated into the chondramides at any detectable level (chapter B-
1). The same stereochemical ambiguity was observed in vivo when CmdF was heterologously 
expressed in M. xanthus, and the newly identified aminomutase enzyme from Cv. metallidurans, 
CmTAL, exhibited similarly imperfect stereoselectivity (chapter B-2). Moreover, SgcC4 has 
been reported to produce minor amounts of (R)--Tyr, which is not incorporated into the enedi-
ynes.[78] Thus, these tyrosine aminomutases evidently fail to create an enantiopure intracellular 
-amino acid pool, and therefore “gatekeeping” mechanisms must be in place to ensure stringent 
stereochemical control of -tyrosine incorporation into the secondary metabolites from C. croca-
tus and S. globisporus.  
In NRPS biosynthetic pathways, the adenylation (A) domains are responsible for the selec-
tion and activation of amino acid building blocks. The CmdD-A7 domain responsible for -
tyrosine incorporation during chondramide biosynthesis (Figure C-2 A) was shown in vitro to 
activate primarily (R)--Tyr, a result that agrees well with the stereoselectivity exhibited by 
CmdF and the (R)-configuration of the -tyrosine moiety in the chondramides.[44] Activity of 
CmdD-A7 towards L-tyrosine and (S)--Tyr was at considerably lower levels. Similarly, the 
SgcC1 A domain which catalyzes the incorporation of -tyrosine during enediyne biosynthesis 
in S. globisporus (Figure C-2 B) exhibits strong kinetic preference for the activation of (S)--
Tyr. The observed activation of the opposite amino acid enantiomers is probably further sub-
strate-limited in vivo. These data argue against an alternative biosynthetic model in which the A 
domains activate L--tyrosine, which would then be isomerized to the -form while tethered to a 
PCP domain on the respective assembly line. Nevertheless, the finding that not even traces of 
the disfavoured enantiomers are found in chondramides and enediynes is astonishing. Thus, ad-
ditional gatekeeping likely occurs in the later stages of the biosynthesis, preventing product for-
mation to proceed with incorporation of the wrong enantiomer. 
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Figure C-2.  Incorporation of -amino acid building blocks during biosynthesis of chondramides (A), the enediyne 
compound C-1027 (B) and andrimid (C). 
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-tyrosine incorporation is the last chain extension step in chondramide biosynthesis before 
the intermediate is released from the assembly line by lactonization. Besides the CmdD-A7 do-
main, three additional functionalities which could exert stereochemical control are present in the 
terminal CmdD module (Figure C-2 A). Following activation as the -aminoacyl adenylate by 
CmdD-A7, the transfer of the -tyrosine monomer onto the integral carrier domain (CmdD-
PCP7) may be subject to stereochemical discrimination, possibly due to spatial constraints. 
Should the “incorrect” -amino acid enantiomer nevertheless become attached to PCP7, then the 
condensation domain CmdD-C7 could act as a gatekeeper, if it catalyzes the elongation of the 
peptidyl intermediate only with the correct enantiomer loaded on the downstream PCP7. Several 
studies have revealed the ability of C domains to exert such stereochemical control.[96,97] Finally, 
the thioesterase (CmdD-TE) might represent a last instance of chiral selectivity, by performing 
cyclization only if an elongated intermediate is presented to it on PCP7 exhibiting the appropriate 
configuration at the -amino stereocenter. Further attempts to clarify the detailed mechanism of 
stereochemical control in the late stage of chondramide biosynthesis would greatly benefit from 
the heterologous expression of combinations of the underlying protein domains and, ideally, the 
PCP6 to TE portion of CmdD (even though the purification of biosynthetic proteins of that size 
is challenging). Synthetic intermediates and activated -amino acid precursors with differing 
chirality could then be enzymatically installed in-vitro on the recombinant partial CmdD mod-
ule,[98] in order to probe its processing capability. 
The above considerations could similarly apply to the biosynthesis of the (S)--Tyr-
containing enediyne product C-1027, although the catalytic domains in the enediyne pathway 
are encoded on discrete proteins.[99] Additional enzymes are involved in hydroxylation and 
chlorination of (S)--Tyr while it is bound to the carrier protein SgcC2 (Figure C-2 B), but at 
least the halogenase SgcC3 has been shown to accept both -Tyr enantiomers.[70,100] In contrast 
to the chondramide and enediyne biosynthetic routes, rigorous chiral gatekeeping seems to occur 
in the early stages of andrimid biosynthesis (Figure C-2 C).[67] In this pathway, an (S)--Phe 
building block is supplied by a phenylalanine ammonia lyase (AdmH), which does not produce 
detectable amounts of the opposite enantiomer. In addition, the A domain responsible for (S)--
Phe selection (AdmJ) does not activate (R)--Phe to any appreciable degree. This two-tiered 
mechanism of stereochemical control apparently compensates the lack of stereselectivity in sub-
sequent biosynthetic steps – indeed, the condensing enzyme AdmF involved in andrimid biosyn-
thesis has been demonstrated to accept both -phenylalanine enantiomers.[67] 
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-amino acids are building blocks in a number of natural products, and their incorporation 
into biologically active peptides has been associated with increased stability toward proteolytic 
degradation.[53,101,102] Moreover, the -amino acid moiety likely constitutes an important struc-
tural feature, reflecting the evolutionary adaption of a compound to a specific biological target. 
Therefore, -amino acid-incorporating A domains represent interesting tools for the construction 
of artificial assembly lines, capable of producing “designed” secondary metabolites. However, 
problems (in particular a reduced yield) are sometimes encountered when domains are excised 
from one biosynthetic multienzyme and inserted into a non-cognate assembly line.[103] To cir-
cumvent such difficulties, the genetic re-engineering of adenylation domains to alter substrate 
specificity has been proposed. Analysis of the substrate binding pockets of A domains has re-
sulted in the identification of eight residues which can be used to predict the activation specific-
ity. The feasibility of manipulating this “non-ribosomal code” through single amino acid muta-
tions, in order to achieve activation of different amino acids, has been demonstrated.[104] 
It has been pointed out, however, that the current predictive model, which is based essen-
tially on the crystal structure of the L--Phe activating domain PheA from the gramicidin path-
way, is perhaps not applicable to -amino acid-activating A domains. While the comparison of 
non-ribosomal codes (Table C-1) reveals slight similarity between certain L--Tyr and -Tyr 
activating A domains, considerable divergence is observed between the -amino acid activating 
domains from different pathways. Interpretation is further hindered by the hitherto small number 
of characterized A domains with -amino acid specificity. Significantly, it may not even be cor-
rect to assume that the same conserved key residues highlighted by the existing model interact 
with the substrate in -amino acid-specific A domains, given the fundamental structural differ-
ence between - and -amino acids. Thus, the crystal structure of an -amino acid activating A 
domain is eagerly awaited and is expected to shed light on the molecular basis for selective acti-
Table C-1. Key residues which de-
termine the substrate specificity of A-
domains that activate L-Phe or L-Tyr, 
and residues found at the corre-
sponding positions in -amino acid 
activating A domains. The domains
originate from the following path-
ways: PheA, gramicidin; tycC, tyro-
cidine; BacC, bacitracin; SgcC1,
enediyne C-1027; CmdD-A7, 
chondramide; AdmJ, andrimid. Num-
bering relates to PheA. 
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vation of -amino acids. The establishment of a non-ribosomal code for -amino acid activating 
A domains is a crucial prerequisite for predicting reliably the incorporation of -amino acids by 
biosynthetic routes revealed through genome mining. Furthermore, this knowledge could facili-
tate future attempts to rationally modify the substrate sepcificity of A domains, with the aim to 
create novel -amino acid-incorporating NPRS assembly lines. 
 
Discovery of novel aminomutases and mutational analysis of CmdF. 
The production of -Tyr and -Phe via aminomutase-catalyzed conversion of the corre-
sponding -amino acids acids, followed by incorporation according to NRPS biosynthetic logic, 
appears to be a common strategy for the formation of natural products which contain aromatic -
amino acids.[67] Thus, the “function-guided” discovery of new aminomutase enzymes from 
strains producing such secondary metabolites should be anticipated. In the course of this work, 
additional tyrosine aminomutases were cloned from two myxovalargin-producing Myxococcus 
strains and from one strain of Cupriavidus metallidurans, thereby expanding the formerly small 
TAM enzyme family.[45] These new data were expected to provide a stronger basis for sequence 
comparison and to pave the way for attempts to manipulate the properties of CmdF by site-
directed mutagenesis. Biochemical characterization revealed that the Myxococcus enzymes pro-
duced (S)--Tyr, consistent with their putative role in supplying an (S)--Tyr building block for 
myxovalargin biosynthesis in these strains. The Cupriavidus enzyme (CmTAL) was shown to 
form preferentially (R)--Tyr, but CmTAL was in fact more efficient as a TAL than a TAM. No-
tably, the secondary TAM activity exhibited by CmTAL distinguishes this enzyme from other 
known TALs. For example, the TAL from Saccharothrix espanaensis, Sam8, did not show any 
aminomutase activity.[73] 
The preferential production of opposite -Tyr enantiomers constitutes a striking difference 
between members of the TAM enzyme family. Very recently, a structural study on SgcC4 has 
established the mechanistic basis for aminomutase catalysis.[77] It has been proposed that stereo-
chemical differentiation results from the attack of an MIO-amine adduct on opposite faces of a 
planar pHCA intermediate, and crystallographic data have confirmed that the active site of 
SgcC4 can accommodate different substrate orientations. On the basis of this model, the stereo-
chemical outcome of the aminomutase reaction should be determined by amino acid residues in 
proximity to the active site, which help to orient the substrate appropriately. However, residues 
which could potentially play such roles are not obvious from the existing structural and bio-
chemical data. 
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Despite the absence of structural data for the myxobacterial aminomutase CmdF (crystallisa-
tion attempts in the course of this study in collaboration with the group of Prof. Schulz, 
Freiburg, yielded diffraction data with insufficient resolution), efforts were made to modulate its 
catalytic properties by site-directed mutagenesis. These experiments were inspired by the recent 
report of a single active site residue which is able to act like a substrate selectivity switch, con-
verting TAL from Rhodobacter into an efficient PAL.[66] A number of CmdF variants were gen-
erated, in which certain conserved motifs found in ammonia lyase or aminomutase enzymes 
were mutated in the corresponding positions in CmdF. It was expected that the mutant CmdF 
enzymes might exhibit altered product specificity (i.e. ammonia lyase versus aminomutase activ-
ity) or modified substrate selectivity, or display a stereoselectivity shift (chapter B-2). Unfortu-
nately, these attempts were largely unsuccessful – in fact, most experiments only allowed the 
general conclusion that the aminomutase scaffold does not readily tolerate the introduction of 
conserved motifs from HAL, PAL, TAL or TAM protein sequences. However, the variation of 
one semiconserved amino acid, Glu399, was found to impact stereoselectivity: Replacement of 
this residue by lysine (CmdFE399K) increased the enantiomeric excess of (R)--Tyr from 69 to 
97% ee, while substitution with methionine (CmdFE399M) promoted racemization (chapter B-2). 
 
Prospects for the genetic manipulation of stereochemical control in TAMs. 
In the following, a possible role of Glu399 in the aminomutase mechanism is illustrated with 
the aid of a homology model for CmdF, which was calculated using the published SgcC4 struc-
ture as a template (Figure C-3 A).[105] Besides the crystal structure of SgcC4,[76] structural data 
also exist for a number of ammonia lyase enzymes.[79,80,106] These crystallographic studies have 
pictured the common aminomutase/ammonia lyase scaffold as a largely -helical bundle (Figure 
C-3 A), and the active form has been described as a homotetramer (a head-to-tail dimer of 
dimers; Figure C-3 B, C). Importantly, the MIO-containing active site has been shown to be 
framed by residues from three of the four subunits in the enzyme complex. Certain key residues 
within interacting distance to the amino acid substrate in the binding pocket have been assigned 
specific functions for aminomutase and/or ammonium lyase catalysis. His83 is the already men-
tioned TAL/PAL “substrate selectivity switch” which has been proposed to direct substrate rec-
ognition in TAL and TAM; structural data for SgcC4 suggest that this residue and Tyr403 (from 
a neighboring protein chain) form a bifurcated hydrogen bond with the tyrosine ring-hydroxyl 
(see also Fig. A-11).[77] Intriguingly, the residue Glu399, which was identified in this thesis as a 
“stereoselectivity modulator” in CmdF, is located on the Tyr403-neighboring helix turn (Figure 
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Figure C-3.  A, homology model for CmdF, using the SgcC4 structure (PDB: 2OHY) as template for SWISS-MODEL. 
The active site MIO is drawn in the space-filling representation (pink). B, arrangement of subunits in the active-form 
tetramer; C, positioning of dimers.  
C-3 A). Thus, replacing Glu399 with amino acids that exhibit significantly altered chemical 
properties and/or steric requirements of their side chains, is likely to have an impact on the elec-
tronic and spatial characteristics of the binding pocket – either directly, or indirectly through re-
positioning of the nearby Tyr403. This influence could induce a change in substrate orientation, 
which would then be reflected by a modified stereochemical course of the aminomutase reac-
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tion. A crystallographic investigation of CmdF and its variants with altered stereoselectivity, 
bound to the inhibitor used in the SgcC4 study, should help to reveal further details and addi-
tional stereochemical determinants.  
It must be pointed out that Glu399 is not strictly conserved in the aminomutases, and the 
amino acid at this position does not correlate with the stereoselectivity exhibited by different 
TAMs. Several independent evolutionary solutions might have been established in Nature, re-
garding the key residues that modulate the structural framework of the active site of TAM en-
zymes (see below). Indeed, a comparison of the amino acid sequences of all TAMs characterized 
to date did not reveal sequence motifs which would allow to predict the stereochemical prefer-
ence by sequence analysis. Therefore, sequence-swapping or directed evolution techniques 
should be employed in future studies on the molecular basis for of stereoselectivity in the TAM 
enzyme family. 
Nonetheless, the finding that a single residue modulates stereocontrol in CmdF is encourag-
ing with respect to possible applications for TAMs, because it indicates the feasibility to tailor 
their catalytic properties and thereby increase their potential as highly stereoselective biocata-
lysts. For example, CmdFE399K could be used for the supply of an (R)--Tyr building block in an 
engineered NRPS pathway. Implementing stringent stereochemical control in such artificial bio-
synthetic routes could prove difficult, and an enantiopure pool of the -amino acid precursor 
might thus be desirable. Another possible application could make use of the “reverse” aminomu-
tase reaction to produce (R)--tyrosine with high enantiomeric excess, starting from coumaric 
acid, the usual product of TAL side activity exhibited by the TAMs. Ideally, ring-hydroxylated 
-Tyr derivatives would also be accessible, using various aromatic acrylic acids as sub-
strates.[107] However, this biotransformation would definitely require thorough optimization of 
the catalyst to achieve significantly higher turnover numbers, in order to become practically use-
ful. The enzymatic synthesis of enantiopure - and -amino acids using recombinant phenyla-
lanine aminomutase (PAM) from Taxus chinensis has been reported very recently.[108] In that 
study, it has been highlighted that the availability of a highly enantioselective aminomutase en-
zyme was a crucial prerequisite to obtain products with satisfactory chiral purity. Interestingly, 
turnover with ring-hydroxylated substrates could not be achieved using PAM – the potential of 
TAM to fill this gap remains to be explored. 
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The tyrosine 2,3-aminomutase enzyme family: evolutionary implications. 
In this work, the TAM enzyme family was extended through the biochemical characteriza-
tion of candidate enzymes from prokaryotic sources, and the increased availability of sequence 
information permitted for the first time a phylogenetic analysis. The TAM family now com-
prises six members, which share the same strict substrate specificity for L-tyrosine, but differ 
significantly with respect to product stereochemistry and relative preference for aminomutase 
versus ammonia lyase activity. An amino acid alignment was compiled which includes all bacte-
rial PAL, TAL and TAM proteins characterized to date (chapter B-2), plus a selection of en-
zymes with confirmed HAL activity (albeit a much higher number of HAL homologs exist in 
publicly accessible databases). Figure C-4 illustrates the outcome of this comparison in the form 
of an unrooted similarity tree. 
Two conclusions may be drawn from this picture. Firstly, the TAM enzymes are located in a 
separate node of the tree, and the branching pattern indicates greater similarity to HALs than to 
TALs and PALs. It has been speculated previously that tyrosine aminomutases may have 
emerged through the evolutionary conversion of a TAL towards tyrosine aminomutase activity, 
Figure C-4.  Phylogenetic comparison of prokaryotic ammonium lyase and aminomutase protein sequences, repre-
sented by an unrooted tree diagram. 
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which would also offer a convenient explanation for the significant ammonia lyase side activity 
exhibited by aminomutases. Contrary to this expectation, the evidence presented here strongly 
suggests that TAMs do not constitute a side-branch of the TAL group, but may instead have 
evolved from a “HAL-like” ancestor. This proposal also appears plausible with regard to the 
widely spread occurence of HAL enzymes in bacteria, which are in fact present in most species, 
while prokaryotic TALs and PALs are extremely rare. Speculations have actually been raised 
about bacterial PALs and TALs being themselves derived from HAL, considering the immense 
phylogenetic distance to their PAL and TAL counterparts of plant origin.[109] 
Secondly, no clustering according to stereochemical preference for the production of (R)- or 
(S)--tyrosine occurs within the TAM family. The observed grouping instead reflects the under-
lying phylogenetic relationships. Notably, the preferred TAM stereoselectivity matches the con-
figuration of a chiral building block found in a secondary metabolite from the respective strain, 
in all instances where such a natural product has been identified to date. In conclusion, the cata-
lytic properties of each individual TAM enzyme may have evolved in order to furnish a specific 
pathway with a -tyrosine building block. Thus, convergent evolution might have taken place: 
characteristic traits of the TAMs could have evolved independently in distant phylogenetic 
clades. This notion implies that specific amino acid substitutions, which bring about this high 
degree of evolutionary diversification within the TAM family, are not necessarily conserved in 
proteins exhibiting the same phenotypic characteristics (i.e., the same stereochemical prefer-
ence). The finding that the known TAM sequences are polyphyletic may therefore explain the 
above-mentioned difficulties to predict signature motifs correlating with the stereoselectivity of 
TAM enzymes from different sources. 
Aminomutase genes are frequently encountered as integral parts or in the immediate vicinity 
of gene clusters encoding -amino acid-incorporating pathways (e.g. chondramide, enediynes, 
and andrimid biosynthesis). This observation indicates the possibility to identify such biosyn-
thetic routes by searching for genes potentially encoding aminomutases – an approach greatly 
facilitated by (but also practicable without) the availability of whole-genome data or metage-
nomic sequence information. In this regard, it is worth mentioning that the biosynthetic path-
ways for myxovalargin production in Myxococcus and jaspamide formation in Jaspis (or in a 
hypothetical bacterial symbiont of this sponge) have yet to be discovered.  
  3. Novel metabolites from S. aurantiaca  
3. Structure and biosynthesis of imidacins – novel secondary metabolites from 
Stigmatella aurantiaca Sg a15 featuring an unique urocanate-moiety 
 
The biosynthesis of microbial secondary metabolites is frequently investigated by a “retro-
biosynthetic” approach: based on a known structure, genes putatively involved in the underlying 
biosynthetic route are first predicted and then searched for in the genome of a producer strain, 
using molecular biological techniques.[33] The increasing availability of genomic sequence in-
formation has further simplified this procedure, facilitating in many cases the in-silico correla-
tion of gene clusters to a given compound. Whole-genome data has also enabled the reverse 
“from genes to products” approach, termed gemome mining: bioinformatic methods are initially 
used to predict biosynthetic assembly lines as well as the approximate structures potentially pro-
duced by these pathways.[110] An attempt is subsequently made to identify the corresponding 
compounds in the metabolite inventory of a strain under investigation. Such approaches can only 
be successfully applied if the genetic information permits reliable forecasts about the monomers 
incorporated by a pathway as well as the type and order of all involved enzymatic transforma-
tions. Consequently, the above procedures are likely to fail when analyzing what is regarded as 
non-textbook biosynthetic routes – i.e., pathways exhibiting a non-contiguous genetic organiza-
tion or encoding superfluous functions. Moreover, biosynthetic routes incorporating unprece-
dented building blocks or employing unfamiliar biochemical transformations cannot be ade-
quately predicted. Importantly, such pathways seem to rather represent the rule then the 
exception and are detected with high frequency in bacterial genomes. 
In this work, an alternative approach, best described as “from precursors to products”, lead 
to the discovery of novel secondary metabolites from S. aurantiaca Sg a15 (chapter B-4). Fol-
lowing inactivation of the general histidine utilization pathway in Sg a15, comparative metabo-
lite profiling highlighted the existence of previously unrecognized compounds, later named imi-
dacins, the production of which depends on the activity of histidine ammonia lyase. Additional 
targeted gene inactivation experiments and the screening of a transposon mutant library, com-
bined with feeding studies, enabled the identification of further genes involved in imidacin for-
mation and allowed to eventually deduce a biosynthetic model (Figure C-5). The obtained ge-
netic information was also used to engineer S. aurantiaca for increased imidacin production – 
this manipulation was actually a crucial factor for the structural elucidation of the imidacins, 
since they were produced only in minute quantities by the wildtype strain. Genes encoding func-
tions for imidacin biosynthesis were  found  distributed  over distant  locations in the  genome of 
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Figure C-5.  A, Genes involved in imidacin biosynthesis (dark grey). White crosses denote targeted gene inactiva-
tions. The reverse black triangle highlight the transposon insertion site. CL, CoA ligase. B, The proposed biosyn-
thetic route for imidacin formation, starting from a novel branching point in bacterial histidine metabolism. HALSa, 
histidine ammonia-lyase; HutU, urocanase; Imd4, proposed cyclopropane synthase; Imd5, putative hydrolase. The 
actual double bond geometry of the precursor processed by Imd4 is not known. 
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S. aurantiaca. Imidacin formation may thus be seen as the result of an interplay between diverse 
biosynthetic functions which are otherwise associated with unrelated metabolic pathways. Sev-
eral uncommon features of this intriguing biosynthetic route are pointed out in the following. 
According to search results from publicly accessible databases, the imidacins represent the 
only natural products known to date to incorporate an imidazole-acryl moiety. This unique sub-
structure was shown in this study to derive directly from urocanic acid, the product of HAL-
catalyzed conversion of  L-histidine. In fact, the identification of urocanate as the starter unit for 
imidacin biosynthesis revealed an unprecedented branching point from the prokaryotic HAL-
dependent histidine degradation pathway into secondary metabolism in S. aurantiaca Sg a15 
(Figure C-5, B). Future studies, using a combined gene inactivation and metabolite profiling ap-
proach as implemented here, should help to clarify whether more urocanate-derived metabolites 
exist in myxobacteria as well as in other bacterial groups. 
For a number of secondary metabolite biosynthesis routes, the recruitment of monomeric 
precursors such as carboxylic acids from primary metabolism has been demonstrated to proceed 
via the activation as acyl-adenylates by AMP-ligases, or as CoA-esters by CoA-ligase en-
zymes.[111] Within the imidacin operon, imd1 was found to encode a putative AMP-ligase do-
main (Figure C-5), and module Imd1 was subsequently shown by targeted inactivation to be es-
sential for imidacin formation. The hypothetical involvement of a CoA-ligase encoded by a gene 
located in close proximity was disproven by targeted inactivation. Imidacin biosynthesis is thus 
proposed to start with the activation of urocanic acid as urocanyl-AMP by Imd1-A, probably 
followed by transfer onto the carrier protein domain Imd1-ACP. This mode of starter unit incor-
poration should be further substantiated through the direct analysis of the loading of urocanate 
onto an excised Imd1-ACP by recombinant Imd1-A in-vitro. High-resolution mass spectrometry 
could then be used to detect the resulting urocanyl-S-ACP. The mass spectrometric interrogation 
of assembly line intermediates bound as thioesters to stand-alone carrier proteins, or tethered to 
integral carrier domains on intact multi-domain enzymes, has been reported recently for a wide 
range of biosynthetic building blocks.[112] If the complete Imd1 module could be heterologously 
expressed and purified, it would be possible to additionally investigate the uncertain role of the 
apparently superfluous Imd1-ER domain by mutation of active-site residues. 
Following activation of the urocanic acid starter unit, the linear scaffold of the imidacins is 
proposed to derive from several rounds of chain extension according to PKS biosynthetic logic 
(chapter B-4). Two imidacin derivatives with chain length differences corresponding to one 
C2H4- unit were found, suggesting that imidacin biosynthesis involves an iterative mechanism 
for carbon chain elongation lacking perfect chain length control. Only one module encoded 
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within the imd operon, Imd2, has the full complement of domains necessary to catalyze chain 
extension plus subsequent ketoreduction, dehydration and enoylreduction (Figure C-5). Addi-
tionally, in silico analysis indicated that the integral Imd2-AT domain likely exhibits substrate 
specificity for malonyl-CoA. Thus, iterative use of module Imd2 could afford the linear, com-
pletely reduced imidacin backbone after six or seven cycles of chain extension and -keto proc-
essing. The iterative use of a bacterial multifunctional type I PKS module has been demonstrated 
first in the biosynthesis of orsellinic acid by S. viridochromogenes.[113] Subsequently, the itera-
Figure C-6.  Secondary metabolites derived in part from iterative type I PKS biosynthetic logic, and functional organi-
zation of the modules proposed to act iteratively in the respective pathways. 
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tive action of a type I PKS system, which usually carries out only one round of catalysis per 
module, has been observed as an aberrant function (termed “stuttering”) in erythromycin biosyn-
thesis.[114] In another early study, iterative type I PKS biochemistry has been shown to be in-
volved in the biosynthesis of stigmatellin from S. aurantiaca.[115] Iterative use of type I PKS 
modules has since then been reported from a growing number of myxobacterial and streptomy-
cete megasynthetases, and is increasingly recognized as a programmed event in type I PKS bio-
synthetic pathways.[59] Selected examples of secondary metabolites which originate in part from 
iterative type I PKS biosynthesis are shown in Figure C-6, along with the domain organization 
of the iteratively acting modules. Modules AurA and BorA5 incorporate two and three methyl-
malonyl-CoA monomers during biosynthesis of aureothin and borrelidin, repectively, but differ 
with respect to the degree of ketoreduction they perform.[116,117] The malonyl-CoA specific 
module DkxN has recently been proposed as one of two iterating modules involved in the bio-
synthesis of the variable-length polyene portion of the DKxanthenes from M. xanthus.[84] In-
triguingly, the polyenic side chain of the myxochromides from S. aurantiaca is synthesized by 
one single module (MchA), representing the only PKS module in the hybrid PKS/NRPS mch 
gene cluster.[85] Although MchA contains an ER domain, this domain is presumably inactive due 
to several mutations in conserved motifs. Thus, iterative use of MchA for seven or eight rounds 
of malonyl-CoA incorporation has been proposed to give rise to the unsaturated C16 to C18 moi-
ety found in the myxochromides S1 – S3. 
In contrast to the aforementioned biosyntheses, the imidacin pathway currently represents 
the only investigated type I PKS biosynthetic route producing a fully reduced and unbranched 
alkyl chain, by the repeated use of one single PKS module. Imidacin formation thus evidently 
mimicks the outcome of fatty acid biosynthesis. The variable length of the imidacin scaffold 
may be explained by a lack of stringent chain length control. This assumption may be addressed 
in future studies, as the mechanisms underlying chain length control in iterative PKS systems 
still await an explanation. 
 The structures of imidacins A1 and A2 comprise a cyclopropane moiety (Figure C-5). Be-
sides certain fatty acids from E. coli, M. tuberculosis and other prokaryotes,[118,119] only a small 
number of bacterial natural products have been shown to contain this structural feature. Exam-
ples include coronatine from P. syringae, curacin from the marine cyanobacterium L. majuscula, 
and ambruticin from S. cellulosum (Figure C-7).[120-122] Despite the rareness of cyclopropane 
rings in microbial secondary metabolites, the biosynthetic routes leading to their formation are 
amazingly diverse. For example, a cryptic chlorination strategy has been proposed for the forma-
tion of the aminocarboxycyclopropane moiety of coronamic acid, the precursor of coronatine 
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(Figure C-7 A).[123] Following enzymatic chlorination by CmaB, the PCP-bound -Cl intermedi-
ate undergoes nucleophilic attack by the -carbon (supported by CmaC), to yield the cyclopro-
pane ring.[120]  Curacin  biosynthesis is also  believed to proceed via a  cyclopropyl-ACP inter-
mediate (Figure C-7 B), but details about the transformation of the proposed 3-methylcrotonyl-
Figure C-7.  A-D, Bacterial metabolites featuring a cyclopropane moiety, and proposed biosynthetic transformations
involved in cycopropane ring formation (A, B, D). 
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ACP precursor have yet to be elucidated.[121] With regard to the biosynthesis of ambruticins 
(Figure C-7 C), it has been hypothesized that formation of the methylcyclopropane ring could be 
induced by a Favorskii rearrangement of an assembly line intermediate; however, nothing is 
known about the enzyme hypothetically involved in establishing the final cyclopropane stereo-
chemistry.[122] 
Notably, enzymes capable of introducing a cyclopropane moiety into unsaturated fatty acid 
scaffolds have been reported from E. coli and M. tuberculosis.[124,125] These S-
adenosylmethionine (SAM)-dependent cyclopropane synthases have been shown to catalyze the 
methylenation (“cyclopropanation”) of unsaturated fatty acid precursors via addition of an 
SAM-derived methyl group to a double bond, followed by rapid proton loss (Figure C-7 D). Due 
to the structural similarity between fatty acids and imidacins, we suggested that this mechanism 
for cyclopropanation could also apply to imidacin biosynthesis (chapter B-4). Therefore, an S. 
aurantiaca Sga15 culture was supplemented with (methyl-d3)-L-methionine to create an intra-
cellular pool of (methyl-d3)-SAM. The observed incorporation of two deuterium labels into the 
imidacins provided strong evidence for the formation of the cyclopropane ring in imidacins via 
SAM-dependent cyclopropanation. The logical substrate for this transformation would be a 3-
unsaturated imidacin precursor, which in turn could derive from a molecule with a completely 
saturated alkyl chain. The mass spectrometric investigation of Sg a15 extracts indicated the exis-
tence of both putative precursors (chapter B-4, Figure S4). Thus, the late steps in imidacin bio-
synthesis most likely include the introduction of an unsual 3-double bound into a fatty acid-like 
precursor and subsequent conversion of this double bond to yield a cyclopropane ring. 
This hypothesis is further corroborated by the fact that a cyclopropane synthase candidate 
enzyme, Imd4, is encoded within the imidacin gene cluster. Imd4 has a conserved SAM binding 
site, but otherwise exhibits rather weak similarity to known cyclopropane synthases. However, 
this divergence might be attributable to the unusual substrate specificity required for imidacin 
conversion. Further characterization of the potentially novel cyclopropane synthase Imd4 should 
be performed in-vitro, using recombinantly produced Imd4 and the unsaturated presursor (ob-
tained through synthesis) as substrate. A plausible candidate enzyme for the required 3-
desaturation step was not identified within the sequenced region, but may instead be encoded 
elsewere in the Sg a15 genome. A feeding study, using the completely saturated imidacin pre-
cursor and the HAL-deficient mutant strain generated in this work, should corroborate the pres-
ence of this 3-desaturase function in Sg a15. Such an enzyme has actually not been reported 
from bacteria to date, but has been characterized very recently, for the first time, from the fungus 
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Fusarium graminearum.[126] Thus, the sequence-guided discovery of a gene encoding the hypo-
thetical imidacin desaturase might be attempted, provided that whole-genome sequence informa-
tion for S. aurantiaca Sg a15 becomes available. At present, the alternative possibility that the 
3-double bond could be incorporated during PKS assembly cannot be excluded. Indeed, certain 
iterative PKS systems have been reported to exhibit a variable behaviour with respect to the oxi-
dation state of the assembly line intermediate, depending on chain length.[52] However, due to 
the rather unusal positioning of the double bond a PKS-derived origin appears less likely. 
Taken together, imidacin biosynthesis was shown to comprise several intriguing transforma-
tions. The pathway exhibits an unusually disintegrated genetic organization, as genes encoding 
functions for precursor supply and post-assembly line modification are located distantly from 
the core biosynthetic gene set. Moreover, the clustered region itself appears partially cryptic, due 
to the non-linear arrangement of modules and the presence of seemingly nonessential genes. 
Therefore, further gene inactivation experiments, using markerless in-frame deletions or point 
mutations, are needed to confirm that genes without a predicted function for imidacin biosynthe-
sis are actually dispensable. However, such efforts are currently hindered by the inavailability of 
the appropriate genetic tools for S. aurantiaca Sg a15. Thus, heterologous expression of the imi-
dacin pathway is envisaged. Genetic manipulation in the heterologous host could then help to 
determine the minimally required gene set and should also allow to confirm the proposed roles 
of certain candidate genes and domains encoded within the cluster. 
Finally, further studies should evaluate the potential biological activity of imidacins. Addi-
tional investigations are also necessary to shed light on the significance of imidacin production 
for Stigmatella aurantiaca. 
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4.  The impact of advanced mass spectrometry-based methods on the analysis of 
microbial natural product diversity 
The last several years have seen an enormous increase in the amount of microbial genomic 
information added to public databases. In light of the current advances in sequencing technol-
ogy, this trend is definitely expected to accelerate further. When analyzing the genomes of many 
bacterial species for the presence of typical secondary metabolite biosynthetic gene clusters, it 
has recently become a common finding that the apparent genetic potential for natural product 
biosynthesis exceeds by far the number of known compounds from a species. This observation 
even holds true for many well-established producers of secondary metabolites.[110] Thus, the dis-
covery of novel metabolites and their subsequent correlation to biosynthetic gene clusters now 
represents the new bottleneck, rather than the process of obtaining the sequence information. 
A strikingly high number of predicted secondary metabolite biosynthesis pathways were also 
revealed in the course of two recent myxobacterial genome-sequencing projects: the genomes of 
Myxococcus xanthus DK1622 and Sorangium cellulosum So ce56 contain at least 18 and 17 pu-
tative PKS, NRPS or hybrid gene loci, respectively.[39,40] In contrast, intense screening efforts 
have so far yielded merely a handful of secondary metabolites from each of these strains. Vari-
ous reasons could account for this discrepancy. Biosynthetic pathways may theoretically be non-
functional due to mutations, thus representing evolutionary artifacts. However, this assumption 
is unlikely for a high proportion of biosynthetic gene clusters in bacteria, since the elimination 
of large, “useless” sequence regions (i.e. defective genes which do not confer a fitness advan-
tage) is expected to occur rapidly in terms of the evolutionary timescale. More likely, low pro-
ductivity may be a reason for non-detectability. Both, biosynthetic routes and metabolic path-
ways for precursor supply, may be down-regulated in the laboratory environment for a number 
of reasons – including nutritional conditions, the generally “unnatural” cultivation parameters 
(liquid medium in shaking flask vs. soil; higher temperature, better aeration), and feedback inhi-
bition. In addition, precursors required to biosynthesize unusual building blocks may not be 
available, or very specific inducers of secondary metabolite production from the natural habitat 
could be missing. Moreover, the produced metabolites could suffer from limited stability in the 
cultivation broth, and they may even be actively degraded by the producer upon prolonged culti-
vation. Some of these issues, namely feedback inhibition and the stability/degradation problem, 
are partly circumvented by the routine addition of adsorber resin to myxobacterial fermentations. 
It should be noted, however, that this widespread practice introduces a certain bias with respect 
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to the metabolite inventory observed from a strain, as it can disproportionally increase the yield 
of well-adsorbed compounds while potentially failing to collect others. 
Another important point of concern relates to the analytical methods used in the past for the 
discovery of natural products from myxobacteria. Over the last decades, the screening of myxo-
bacterial extracts has largely relied on bioassays and HPLC-coupled UV/Vis detection. Activity-
guided screening is convenient because it can directly deliver candidate compounds for a spe-
cific biological activity – however, this approach is inherently biased by the choice of assays and 
targets. HPLC-UV/Vis-based screening, on the other hand, inevitably fails to highlight com-
pounds without “eye-catching” light-absorption characteristics. In addition, it cannot identify 
minor constituents in complex mixtures. Significantly, it is highly desirable to reliably detect 
compounds regardless of their biological activity and in spite of their low abundance, when the 
aim is to correlate a strain’s compound inventory to its genetic capacity for the production of 
secondary metabolites. 
 Modern liquid chromatography-coupled electrospray ionization mass spectrometry (LC-
ESI-MS) offers a solution to this challenge, as it can in principle detect a highly diverse range of 
chemical compounds with high sensitivity. Depending on the MS platform used, different ap-
proaches may be chosen to screen bacterial metabolite profiles. Fragmentation patterns derived 
from data-dependent tandem-MS measurements have occassionally been employed for com-
pound identification.[127] However, it should be pointed out that the self-limitation to compounds 
giving rise to sufficiently intense signals for automatic MS2-fragmentation, represents a severe 
shortcoming of this strategy. Therefore, a different approach for the analysis of myxobacterial 
extracts was devised in this work (chapters B-6 and B-7). Using data from high-resolution LC-
ESI-ToF measurements, compound identification was accomplished through the combined 
evaluation of accurate mass values and isotope patterns. In addition, retention times were incor-
porated as an orthogonal analytical parameter. Importantly, the implementation of high-
resolution LC-MS also permitted the semi-quantitative treatment of all obtained data, without 
the need to define in advance the specific signals to monitor.[128] Moreover, a compound finding 
algorithm was applied to the high-resolution LC-MS data, thereby creating a “sample inventory” 
which contained both known substances and potentially novel compounds. This processing step 
in turn facilitated the subsequent statistical interpretation by Principal Component Analysis 
(PCA) (chapter B-7). 
Because of the aforementioned possibilities, LC-coupled high-resolution MS techniques 
similar to the methods employed in this work are now increasingly used for a range of metabolic 
profiling applications.[128-130] In contrast, statistical methods for the mining of LC-MS data cur-
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rently appear to be underutilized in screening projects aimed at the discovery of novel natural 
products from bacteria. 
 
Discovering the hidden secondary metabolome of Myxococcus xanthus. 
Myxococcus xanthus is the biologically best characterized myxobacterium to date, but in 
terms of known secondary metabolites this species apparently lags behind other established 
myxobacterial producers, such as Sorangium cellulosum. Nevertheless, genomic mining has re-
vealed the considerable potential of M. xanthus for the production of secondary metabolites, as 
judged by the presence of at least 18 PKS, NRPS or hybrid gene clusters in the genome of the 
model strain DK1622.[131] To date, five secondary metabolite classes have been identified in ex-
tracts from DK1622, and the availability of whole-genome information has greatly facilitated 
their correlation to biosynthetic gene clusters. These known compounds are the myxochelins, the 
myxalamids, the myxovirescins, the myxochromides, and the DKxanthenes.[84,132-135] Encourag-
ingly, a recent global gene expression study has provided evidence that many of the predicted 
natural product assembly lines in DK1622, which could so far not be correlated to metabolites, 
are actually active under vegetative growth conditions.[136] Consistent with this finding, a previ-
ous proteomic study also suggested that many gene clusters are expressed, since the correspond-
ing peptides could be identified by mass spectrometric analysis.[137] Taken together, the com-
bined data from these two studies provide evidence that most of the secondary metabolite gene 
clusters (i.e. 17 out of 18) in M. xanthus DK1622 are not silent in the laboratory environment. 
Nevertheless, only five natural products have been identified to date. Thus, it was anticipated 
that the application of improved LC-MS-based methods to M. xanthus extracts should lead to the 
Figure C-8.  A, Global distribution of sampling sites from which the 98 M. xanthus strains in this study originated.
Multiple isolates from regional or local spatial ranges were sumamrized as single spots. B, Diversity accumulation 
curves, based on the distribution of non-ubiquituous compounds in 98 samples. Each data point represents the aver-
age number of discovered compounds that would result if n samples were taken (see also chapter B-6). 
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discovery of novel compounds. However, a comparative profiling study which involved knock-
out mutants of all predicted biosynthetic gene clusters in M. xanthus DK1622, did not succeed to 
disclose further candidate metabolites (Nina Cortina, DK and RM, unpublished results). 
A different approach to discover the hidden secondary metabolite inventory of M. xanthus 
was therefore taken. The metabolite profiles of 98 M. xanthus strains that originated from 78 lo-
cations worldwide were compared, and 20 centimeter-scale isolates from one location (Tübin-
gen, Germany) were also included in this screen (Figure C-8, A). This study had in fact two ob-
jectives: firstly, to determine whether there is significant potential for novel compound 
discoveries in other strains besides DK1622 (e.g. if these other strains exhibit increased yield); 
and secondly, to compare the intraspecific diversity of M. xanthus metabolite profiles on global 
versus local scales. 
Targeted screening revealed the presence of four known secondary metabolites (myxochro-
mides, myxochelins, myxalamids, DKxanthenes) in all 98 M. xanthus extracts, while only three 
natural products (althiomycin, cittilin, myxovirescin) exhibited a non-ubiquitous pattern.[48] 
Thus, the known natural products seemed to contribute rather marginally to secondary metabo-
lite diversity in M. xanthus. On the contrary, the statistical evaluation of all LC-MS datasets, im-
plementing a compound-based PCA approach, revealed 37 additional non-ubiquitous com-
pounds representing putative novel metabolites (chapter B-6).[48] The diversity-oriented LC-MS 
based screening approach presented here thus uncovered a strikingly high level of intraspecific 
diversity in the secondary metabolome of M. xanthus. Accordingly, the species M. xanthus 
should be regarded as a promising source of as yet unidentified natural products, in agreement 
with the previous findings from genomic, transcriptomic and proteomic studies with DK1622. 
By applying basic population statistics to the matrix of observed M. xanthus “chemotypes”, 
it was estimated that the 37 newly reported candidate compounds are likely to constitute ~80% 
of the total secondary metabolome diversity in M. xanthus (Figure C-8, B). The metabolite pro-
files of the 20 local isolates were more similar to each other than to most of the global isolates, 
but the centimeter-scale population nonetheless housed substantial metabolite diversity. This 
finding is consistent with the result of a recent study on the genetic population structure of M. 
xanthus on the centimeter scale, which concluded that M. xanthus cells are “surrounded in soil 
by a wide range of genetically distinct conspecifics”.[138] Interestingly, the average degree of 
chemotype similarity among strain pairs isolated within the meter-scale range at the same loca-
tion was not significantly different from that among global-scale strain pairs. Thus, much mixing 
of global chemotypes seems to occur at the meter scale. In conclusion, intense sampling at indi-
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vidual sites may substantially increase the estimate of the total number of metabolites beyond 
that obtained from analysis of single samples from many sites (Figure C-8, B). 
In this study, all observations (i.e. high-resolution m/z signals at specific retention times in 
an LC-MS dataset) constituting a distinct difference between the metabolite profiles of two or 
more strains were regarded as indicating putative compounds of interest, and proposed molecu-
lar formulae served as descriptors for the novel compounds. For a number of reasons, the struc-
tural elucidation of all these compounds and their correlation to a biosynthetic gene cluster may 
not be a straightforward undertaking (chapter B-6). However, the finding that several putative 
compounds occur with a very similar pattern, and additionally exhibit similar retention times 
plus molecular formulae is suggestive of “biosynthetically meaningful” differences. In addition, 
it indicates that at least some of these candidate compounds are likely to be secondary metabo-
lites synthesized by PKS and/or NRPS biosynthetic routes. Intriguingly, the targeted analysis of 
extracts from M. xanthus DK1622, utilizing the list of 37 candidate metabolites highlighted by 
the species-wide screen, revealed this strain as a low-level producer of 10 of these compounds. 
Follow-up studies aimed at identifying the corresponding biosynthetic gene clusters are now be-
ginning to correlate genes to compound masses (Nina Cortina, DK and RM, personal communi-
cation). Thus, the diversity-oriented screening approach devised here can help to discover the 
products assembled by biosynthetic pathways which could not previously be correlated to a spe-
cific secondary metabolite. 
 
The analytical framework for metabolomics-based mining of the myxobacterial secon-
dary metabolite inventory: basic considerations and outlook. 
Metabolomics studies in principle aim at generating a quantitative molecular phenotype for 
an organism under investigation.[130] In the context of bacterial natural product research, primar-
ily the secondary metabolome is of interest. It may be defined as the full range of small mole-
cules released by a strain into the surrounding medium which are neither end products nor in-
termediates of primary metabolic pathways. The secondary metabolome thus represents a subset 
of the extracellular metabolome, and is commonly analyzed as an integral part of the latter. Con-
sequently, sample complexity is generally high and is oftentimes increased further by the pres-
ence of abundant matrix compounds derived from cultivation broth, which may occasionally 
even dominate a sample in terms of signal strength. Thus, studies of the bacterial secondary me-
tabolome require techniques with high resolving power and sensitivity.[139] In the last several 
years, this demand has been increasingly met by combining advanced liquid chromatography 
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techniques (i.e. UPLC using sub-2 µm particle size colums) with high-resolution mass spectro-
metric detection.[140] The utility of such an analytical platform was demonstrated in the M. xan-
thus study discussed in the preceeding section. In comparison to bioassay-guided approaches or 
UV/Vis screening, metabolomics-style experiments based on mass spectrometry are far less bi-
ased with respect to the properties of the detected compounds. However, a certain bias is always 
introduced by the sample preparation procedure and by the analytical setup (e.g. choice of sta-
tionary and mobile phase, ionization, mass range). To address the latter issue, a metabolomics 
experiment with the highest possible coverage of “chemical space” may require an individual 
sample to be analyzed using multiple instrumental configurations. With regard to the characteri-
zation of myxobacterial secondary metabolomes, the potential benefit of changing certain key 
attributes of the analytical system remains to be evaluated in the future. For example, negative 
electrospray ionization or APCI could be used in addition to the standard positive ESI. The im-
plementation of nano-electrospray ionization (nanoESI) appears especially promising, as it af-
fords reduced in-source fragmentation of labile compounds and less unwanted adduct formation 
along with superior sensitivity (DK, unpublished observations). 
Metabolomic studies may adopt different strategies, commonly termed the “targeted” and the 
“comprehensive” approach. The former is often selective for certain compound classes, such as 
amino acids or lipids, and the analysis is usually limited to a number of known compounds. In 
the second approach, also called “quantitative metabolomics”, the focus is on attempting to iden-
tify and quantify as many compounds in a given sample as possible.[130] The worldwide LC-MS 
survey of M. xanthus metabolite diversity which was performed in this work clearly falls in the 
second category (although “targeted screening” was also employed). In such comprehensive 
studies, the implementation of statistical tools for data evaluation is crucial. One statistical 
method which has been previously used in metabolomic applications is Principal Component 
Analysis (PCA). As explained earlier, PCA is a multivariate method for the classification of 
samples which acts like a statistical filter for LC-MS data, pointing towards compounds repre-
senting the most significant differences between samples. However, the essential challenge is to 
properly prepare LC-MS data, which always contain a considerable degree of “chemical noise”, 
for statistical evaluation. Pre-processing of high-resolution data can be accomplished by apply-
ing a compound finder algorithm (a procedure also referred to as “chemical feature detec-
tion”).[141] Statistical interpretation is then carried out on the resulting matrix, representing the 
distribution of all putative compounds (denoted by an exact mass/retention time pair plus an in-
tensity value) in all samples. It was one objective of this work to evaluate the effectiveness of a 
new integrated compound-finding/PCA strategy for the characterization of myxobacterial me-
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Figure C-9.  The analytical framework for LC-MS based mining of myxobacterial secondary metabolomes. 
tabolite profiles. The results clearly demonstrated that the “compound-based bucketing” ap-
proach devised here can indeed generate meaningful output using high-resolution LC-MS data 
derived from complex M. xanthus samples. Furthermore, the compound-based PCA strategy was 
shown to be superior to a more conventional “rectangular bucketing” approach (chapter B-7). 
Besides the discovery of strain-specific metabolites, as carried out in the diversity-oriented 
screening approach with M. xanthus, the identification of compounds giving rise to distinct dif-
ferences in a set of highly complex samples is an important concern in a number of typical ap-
plications related to the investigation of secondary metabolite biosynthesis in myxobacteria 
(Figure C-9). For example, the metabolite profiles from a library of bacterial clones, generated 
by targeted knockout of candidate biosynthetic genes could be analyzed for the absence of spe-
cific metabolites relative to the wildtype strain. Even without any information about biosynthetic 
genes, samples for such an analysis can be generated by random gene inactivation using transpo-
son mutagenesis. Furthermore, quantitative variation in secondary metabolomes could be ad-
dressed through high-resolution LC-MS measurements with subsequent interpretation by PCA, 
providing the opportunity to assay changes in metabolite production pattern in response to dif-
ferent nutritional conditions – notably, without the need to define a priori the specific com-
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pounds to monitor. Similarly, a metabolomics-based approach seems appropriate for investigat-
ing the molecular basis for regulation of secondary metabolite biosynthesis in myxobacteria in 
the future. Finally, PCA-based LC-MS data mining could also become useful for comparative 
metabolite profiling in the course of heterologous expression projects. It is an obvious prerequi-
site for all these applications that the strains under investigation exhibit reproducible growth and 
production characteristics (ideally even when using a miniaturized cultivation setup). These re-
quirements are generally not a problem when working with M. xanthus. However, they impose a 
certain limitation on the applicability of PCA-based LC-MS experiments, considering the ex-
tremely slow and sometimes irregular growth characteristics experienced from a number of 
myxobacterial species, like S. cellulosum and C. crocatus. 
It has to be pointed out that the result of PCA, owing to its essentially unsupervised nature, 
may in some cases not reflect the meaningful differences between samples, in relation to the un-
derlying experimental design. This can particularly occur in sample sets where intense variation 
exists within highly abundant matrix compounds – the random variation may then supersede the 
subtle, but systematic differences pointing at the relevant metabolites. In such cases, it is neces-
sary to manually curate a PCA model by exclusion of compounds that give rise to random varia-
tion, thereby adding a certain degree of supervision. If the respective experiment is based on 
groups of replicate samples, this refinement procedure might even be performed automatically 
by excluding compounds responsible for a large degree of group-internal variance (albeit it 
seems that this possibility is not currently realized in the available PCA software packages). Al-
ternatively, it may also be feasible to directly query the comprehensive compound list generated 
from a sample set (the so-called “bucket table”), with the aim to filter out compounds exhibiting 
a defined occurrence pattern (e.g., creating a list of compounds present in all samples belonging 
to the wildtype group, but systematically absent from all samples in one “knockout” group). 
Once a putative compound of interest has been highlighted by statistical data evaluation, 
high-resolution measurements allow the direct calculation of a molecular formula proposal, thus 
facilitating compound identification. The generation of molecular formulae for putative novel 
compounds with high confidence due to the evaluation of both exact mass and isotopic pattern 
has been exemplified throughout this work as an important key for de-replication and prioritiza-
tion of candidate compounds for further characterization. In addition, tandem-MS measurements 
may be employed to confirm a compound identification. They can also serve to obtain initial 
information about the structure of unknown compounds (e.g. peptide-like fragmentation pat-
tern), possibly in combination with feeding studies employing isotopically labeled precursors. 
The ability of novel mass spectrometers such as the linear trap-orbitrap or quadru-
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pole/quadrupole-ToF devices to perform multi-stage fragmentation meaurements at high resolu-
tion, is especially advantageous in this respect. 
Taken together, metabolomics-based approaches to mining the myxobacterial metabolite in-
ventory, implementing advanced LC-coupled high-resolution mass spectrometry techniques in 
combination with improved statistical tools, are likely to contribute to the future discovery of 
novel natural products from myxobacterial species. Likewise, the in-depth investigation of 
myxobacterial secondary metabolomes looks set to enhance our understanding of various as-
pects of secondary metabolite production in myxobacteria. 
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